Nebulabio Offers Series of Drug Antibody References
Drug Antibody & It's Structure
Drug Antibody, also known as therapeutic antibodies, are biologically engineered proteins designed to specifically target and bind to antigens, such as proteins or cells, involved in diseases. Antibody drugs can be used to treat a wide range of conditions, including cancers, autoimmune diseases, infectious diseases, and inflammatory disorders. Molecular structures are including following types:
(1) Fully murine monoclonal antibodies and human-murine chimeric antibodies, such as Muromonab-CD3 (a fully murine monoclonal antibody) and Rituximab (a human-murine chimeric antibody);
(2) Antibodies with a higher degree of humanization, such as Trastuzumab and Nimotuzumab;
(3) Fully humanized antibodies, which are entirely encoded by human genes and significantly reduce immunogenicity, such as Adalimumab;
(4) Other forms of molecules, including antibody fusion proteins, antibody-drug conjugates, bispecific antibodies, small molecule antibody fragments and nanobodies.
Key Features of Antibody Drugs
Specificity: They bind to specific antigens with high precision, minimizing off-target effects.
Versatility: Antibody drugs can be engineered for various functions, such as blocking signaling pathways, recruiting immune cells, or delivering cytotoxic agents.
Diversity: They include monoclonal antibodies (mAbs), polyclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and more.
Low Toxicity: Due to their specificity, they often have fewer side effects compared to traditional small-molecule drugs.
Antibody drug reference standards play a critical role in drug development, production, and quality control
(1) Candidate Screening in Drug Development: Used to evaluate the activity, specificity, and affinity of candidate antibodies; Help understand the mechanism of action and biological functions of antibodies; Serve as a reference in antibody engineering to optimize structure and function.
(2) Production Process: Serve as a reference to optimize production conditions; Used to monitor consistency and stability during the production process.
(3) Quality Control: Assess the potency and activity of the drug; Detect impurities and degradation products; Evaluate the stability of the drug under different conditions.
(4) Pharmacodynamic Studies: Help determine safe and effective dosages; Serve as a reference to assess potential efficacy.
Nebula Biotechnology Co., Ltd. possesses an abundant collection of standard samples for drug antibody research, all of which are expressed through CHO or HEK293 cells. These samples boast a purity level exceeding 99%, with endotoxin levels lower than 1 EU/mg, making them suitable for various in vivo and in vitro validation tests.
Drug Antibody Name | Target | Product Name | Catalog Number |
Enapotamab | AXL | Human ALX Antibody (Enapotamab, Research Use) | NBR-0001 |
Tilvestamab | AXL | Human ALX Antibody (Tilvestamab, Research Use) | NBR-0002 |
Alsevalimab | VTCN1 | Human B7-H4 Antibody (Alsevalimab, Research Use) | NBR-0003 |
GSK2857916 | TNFRSF17 | Human BCMA Antibody (GSK2857916, Research Use) | NBR-0004 |
LFB patent anti-BDCA-2 | BDCA-2 | Human BDCA-2 Antibody (LFB patent anti-BDCA-2, Research Use) | NBR-0005 |
BIIB059 | BDCA-2 | Human BDCA-2 Antibody (BIIB059, Research Use) | NBR-0006 |
Inebilizumab | CD19 | Human CD19 Antibody (Inebilizumab, Research Use) | NBR-0007 |
Tafasitamab | CD19 | Human CD19 Antibody (Tafasitamab, Research Use) | NBR-0008 |
Rituximab | CD20 | Human CD20 Antibody (Rituximab, Research Use) | NBR-0009 |
Obinutuzumab | CD20 | Human CD20 Antibody (Obinutuzumab, Research Use) | NBR-0010 |
Cixutumumab | IGF-1R | Human IGF-1R Antibody (Cixutumumab, Research Use) | NBR-0011 |
Inotuzumab | CD22 | Human CD22 Antibody (Inotuzumab, Research Use) | NBR-0012 |
Varlilumab | CD27 | Human CD27 Antibody (Varlilumab, Research Use) | NBR-0013 |
Brentuximab | CD30 | Human CD30 Antibody (Brentuximab, Research Use) | NBR-0014 |
Vadastuximab | CD33 | Human CD33 Antibody (Vadastuximab, Research Use) | NBR-0015 |
Naratuximab | CD37 | Human CD37 Antibody (Naratuximab, Research Use) | NBR-0016 |
Daratumumab | CD38 | Human CD38 Antibody (Daratumumab, Research Use) | NBR-0017 |
Magenta patent anti-CD5 | CD5 | Human CD5 Antibody (Magenta patent anti-CD5, Research Use) | NBR-0018 |
Persongen patent anti-CD7 | CD7 | Human CD7 Antibody (Persongen patent anti-CD7, Research Use) | NBR-0019 |
Vorsetuzumab | CD27L / CD70 | Human CD27L / CD70 Antibody (Vorsetuzumab, Research Use) | NBR-0020 |
Amivantamab | c-Met / HGFR | Human c-Met / HGFR Antibody (Amivantamab, Research Use) | NBR-0021 |
Telisotuzumab | c-Met / HGFR | Human c-Met / HGFR Antibody (Telisotuzumab, Research Use) | NBR-0022 |
Onartuzumab | c-Met / HGFR | Human c-Met / HGFR Antibody (Onartuzumab, Research Use) | NBR-0023 |
Pamrevlumab | CTGF | Human CTGF Antibody (Pamrevlumab, Research Use) | NBR-0024 |
Ipilimumab | CTLA-4 | Human CTLA-4 Antibody (Ipilimumab, Research Use) | NBR-0025 |
Quetmolimab | CX3CL1 | Human CX3CL1 Antibody (Quetmolimab, Research Use) | NBR-0026 |
Ulocuplumab | CXCR4 | Human CXCR4 Antibody (Ulocuplumab, Research Use) | NBR-0027 |
MEN1309 | DEC-205 | Human DEC-205 Antibody (MEN1309, Research Use) | NBR-0028 |
CDX-1401 | DEC-205 | Human DEC-205 Antibody (CDX-1401, Research Use) | NBR-0029 |
Rovalpituzumab | DLL3 | Human DLL3 Antibody (Rovalpituzumab, Research Use) | NBR-0030 |
Dragonfly patent anti-DLL3 | DLL3 | Human DLL3 Antibody (Dragonfly patent anti-DLL3, Research Use) | NBR-0031 |
Conatumumab | DR5 | Human DR5 / TRAILR2 Antibody (Conatumumab, Research Use) | NBR-0032 |
Tigatuzumab | DR5 / TRAILR2 | Human DR5 / TRAILR2 Antibody (Tigatuzumab, Research Use) | NBR-0033 |
Cetuximab | EGFR | Human EGFR Antibody (Cetuximab, Research Use) | NBR-0034 |
MEDI-547 | EphA2 | Human EphA2 Antibody (MEDI-547, Research Use) | NBR-0035 |
Sanofi Aventis patent anti-EphA2 | EphA2 | Human EphA2 Antibody (Sanofi Aventis patent anti-EphA2, Research Use) | NBR-0036 |
Rozanolixizumab | FcRn | Human FcRn Antibody (Rozanolixizumab, Research Use) | NBR-0037 |
Bemarituzumab | FGFR2 | Human FGFR2 Antibody (Bemarituzumab, Research Use) | NBR-0038 |
Aprutumab | FGFR2 | Human FGFR2 Antibody (Aprutumab, Research Use) | NBR-0039 |
Farletuzumab | FRA | Human FRA Antibody (Farletuzumab, Research Use) | NBR-0040 |
Mirvetuximab | FRA | Human FRA Antibody (Mirvetuximab, Research Use) | NBR-0041 |
Codrituzumab | GPC3 | Human GPC3 Antibody (Codrituzumab, Research Use) | NBR-0042 |
Disitamab | HER2 | Human HER2 Antibody (Disitamab, Research Use) | NBR-0043 |
Zanidatamab | HER2 | Human HER2 Antibody (Zanidatamab, Research Use) | NBR-0044 |
Trastuzumab | HER2 | Human HER2 Antibody (Trastuzumab, Research Use) | NBR-0045 |
Pertuzumab | HER2 | Human HER2 Antibody (Pertuzumab, Research Use) | NBR-0046 |
Ordesekimab | IL-15 | Human IL-15 Antibody (Ordesekimab, Research Use) | NBR-0047 |
Brodalumab | IL-17RA | Human IL-17RA Antibody (Brodalumab, Research Use) | NBR-0048 |
GSK 1070806 | IL-18 | Human IL-18 Antibody (GSK 1070806, Research Use) | NBR-0049 |
Nidanilimab | IL-1RAP | Human IL-1RAP Antibody (Nidanilimab, Research Use) | NBR-0050 |
Lilly patent anti-IL-21 | IL-21 | Human IL-21 Antibody (Lilly patent anti-IL-21, Research Use) | NBR-0051 |
Clazakizumab | IL-6 | Human IL-6 Antibody (Clazakizumab, Research Use) | NBR-0052 |
Vobarilizumab | IL-6R | Human IL-6R Antibody (Vobarilizumab, Research Use) | NBR-0053 |
Sarilumab | IL-6R | Human IL-6R Antibody (Sarilumab, Research Use) | NBR-0054 |
Tocilizumab | IL-6R | Human IL-6R Antibody (Tocilizumab, Research Use) | NBR-0055 |
Lirilumab | KIR | Human KIR Antibody (Lirilumab, Research Use) | NBR-0056 |
Lacutamab | KIR3DL2 | Human KIR3DL2 Antibody (Lacutamab, Research Use) | NBR-0057 |
MSC-1 | LIF | Human LIF Antibody (MSC-1, Research Use) | NBR-0058 |
Merck patent anti-ILT3 complex | LILRB4 | Human LILRB4 Antibody (Merck patent anti-ILT3 complex, Research Use) | NBR-0059 |
U.Texas patent anti-LILRB4 | LILRB4 | Human LILRB4 Antibody (U.Texas patent anti-LILRB4, Research Use) | NBR-0060 |
Lacnotuzumab | M-CSF | Human M-CSF Antibody (Lacnotuzumab, Research Use) | NBR-0061 |
Enfortumab | Nectin-4 | Human Nectin-4 Antibody (Enfortumab, Research Use) | NBR-0062 |
Tesnatilimab | NKG2D | Human NKG2D Antibody (Tesnatilimab, Research Use) | NBR-0063 |
Oleclumab | NT5E | Human NT5E Antibody (Oleclumab, Research Use) | NBR-0064 |
Spartalizumab | PD-1 | Human PD-1 Antibody (Spartalizumab, Research Use) | NBR-0065 |
Camrelizumab | PD-1 | Human PD-1 Antibody (Camrelizumab, Research Use) | NBR-0066 |
Pembrolizumab | PD-1 | Human PD-1 Antibody (Pembrolizumab, Research Use) | NBR-0067 |
Nivolumab | PD-1 | Human PD-1 Antibody (Nivolumab, Research Use) | NBR-0068 |
MOR-8457 | PDGFB | Human PDGFB Antibody (MOR-8457, Research Use) | NBR-0069 |
Avelumab | PD-L1 | Human PD-L1 Antibody (Avelumab, Research Use) | NBR-0070 |
MDX-1105 | PD-L1 | Human PD-L1 Antibody (MDX-1105, Research Use) | NBR-0071 |
Atezolizumab | PD-L1 | Human PD-L1 Antibody (Atezolizumab, Research Use) | NBR-0072 |
Durvalumab | PD-L1 | Human PD-L1 Antibody (Durvalumab, Research Use) | NBR-0073 |
Genentech anti-PMEL17 | PMEL17 | Human PMEL17 Antibody (Genentech anti-PMEL17, Research Use) | NBR-0074 |
Novartis patent anti-PMEL17 | PMEL17 | Human PMEL17 Antibody (Novartis patent anti-PMEL17, Research Use) | NBR-0075 |
Inclacumab | P-Selectin | Human P-Selectin Antibody (Inclacumab, Research Use) | NBR-0076 |
Crizanlizumab | P-Selectin | Human P-Selectin Antibody (Crizanlizumab, Research Use) | NBR-0077 |
Neihulizumab | PSGL1 | Human PSGL1 Antibody (Neihulizumab, Research Use) | NBR-0078 |
Rosopatamab | PSMA | Human PSMA Antibody (Rosopatamab, Research Use) | NBR-0079 |
Elezanumab | RGMA | Human RGMA Antibody (Elezanumab, Research Use) | NBR-0080 |
Zilovertamab | ROR1 | Human ROR1 Antibody (Zilovertamab, Research Use) | NBR-0081 |
NC318 | Siglec-15 | Human Siglec-15 Antibody (NC318, Research Use) | NBR-0082 |
Lirentelimab | Siglec-8 | Human Siglec-8 Antibody (Lirentelimab, Research Use) | NBR-0083 |
Elotuzumab | SLAMF7 | Human SLAMF7 Antibody (Elotuzumab, Research Use) | NBR-0084 |
Tiragolumab | TIGIT | Human TIGIT Antibody (Tiragolumab, Research Use) | NBR-0085 |
Adalimumab | TNFa | Human TNFa Antibody (Adalimumab, Research Use) | NBR-0086 |
Infliximab | TNFa | Human TNFa Antibody (Infliximab, Research Use) | NBR-0087 |
Bevacizumab | VEGFA | Human VEGFA Antibody (Bevacizumab, Research Use) | NBR-0088 |
Ramucirumab | KDR / VEGFR2 | Human KDR / VEGFR2 Antibody (Ramucirumab, Research Use) | NBR-0089 |
Utomilumab | 4-1BB | Human 4-1BB Antibody (Utomilumab, Research Use) | NBR-0090 |
Urelumab | 4-1BB | Human 4-1BB Antibody (Urelumab, Research Use) | NBR-0091 |
Abbvie patent anti-TNFSF9 | 4-1BBL | Human 4-1BBL Antibody (Abbvie patent anti-TNFSF9, Research Use) | NBR-0092 |
DS-6016a | ACVR1 | Human ACVR1 Antibody (DS-6016a, Research Use) | NBR-0093 |
Ab-14E1 | ACVR2A | Human ACVR2A Antibody (Ab-14E1, Research Use) | NBR-0094 |
Bimagrumab | ACVR2B | Human ACVR2B Antibody (Bimagrumab, Research Use) | NBR-0095 |
Praluzatamab | ALCAM | Human ALCAM Antibody (Praluzatamab, Research Use) | NBR-0096 |
AT002 | ALCAM | Human ALCAM Antibody (AT002, Research Use) | NBR-0097 |
Ascrinvacumab | ALK-1 | Human ALK-1 Antibody (Ascrinvacumab, Research Use) | NBR-0098 |
Cinpanemab | Alpha-synuclein | Human Alpha-synuclein Antibody (Cinpanemab, Research Use) | NBR-0099 |
Prasinezumab | Alpha-synuclein | Human Alpha-synuclein Antibody (Prasinezumab, Research Use) | NBR-0100 |
Nesvacumab | Angiopoietin-2 | Human Angiopoietin-2 Antibody (Nesvacumab, Research Use) | NBR-0101 |
Evinacumab | Angiopoietin-like3 | Human Angiopoietin-like3 Antibody (Evinacumab, Research Use) | NBR-0102 |
Dezamizumab | APCS | Human APCS Antibody (Dezamizumab, Research Use) | NBR-0103 |
BION-1301 | APRIL | Human APRIL Antibody (BION-1301, Research Use) | NBR-0104 |
Enoblituzumab | B7-H3 | Human B7-H3 Antibody (Enoblituzumab, Research Use) | NBR-0105 |
Onvatilimab | B7-H5 / VISTA | Human B7-H5 / VISTA Antibody (Onvatilimab, Research Use) | NBR-0106 |
Dartmouth patent anti-B7-H6 | B7-H6 | Human B7-H6 Antibody (Dartmouth patent anti-B7-H6, Research Use) | NBR-0107 |
Belimumab | BAFF | Human BAFF Antibody (Belimumab, Research Use) | NBR-0108 |
U.Toronto patent anti-Bax | Bcl-2 | Human Bcl-2 Antibody (U.Toronto patent anti-Bax, Research Use) | NBR-0109 |
RG7992 | Beta-Klotho | Human Beta-Klotho Antibody (RG7992, Research Use) | NBR-0110 |
NGM313 | Beta-Klotho | Human Beta-Klotho Antibody (NGM313, Research Use) | NBR-0111 |
XmAb 5592 | BST2 | Human BST2 Antibody (XmAb 5592, Research Use) | NBR-0112 |
Sutimlimab | C1s | Human C1s Antibody (Sutimlimab, Research Use) | NBR-0113 |
G2_anti-C5aR | C5aR | Human C5aR Antibody (G2_anti-C5aR, Research Use) | NBR-0114 |
HKT288+D116 | Cadherin-6 | Human Cadherin-6 Antibody (HKT288+D116, Research Use) | NBR-0115 |
Girentuximab | CAIX | Human CAIX Antibody (Girentuximab, Research Use) | NBR-0116 |
Fsn0503h | Cathepsin S | Human Cathepsin S Antibody (Fsn0503h, Research Use) | NBR-0117 |
VLST-002 | CCL5 | Human CCL5 Antibody (VLST-002, Research Use) | NBR-0118 |
Plozalizumab | CCR2 | Human CCR2 Antibody (Plozalizumab, Research Use) | NBR-0119 |
Mogamulizumab | CCR4 | Human CCR4 Antibody (Mogamulizumab, Research Use) | NBR-0120 |
R707 | CCR7 | Human CCR7 Antibody (R707, Research Use) | NBR-0121 |
LOP628 | CD117 | Human CD117 Antibody (LOP628, Research Use) | NBR-0122 |
SNG-CD123A | IL-3RA | Human IL-3RA Antibody (SNG-CD123A, Research Use) | NBR-0123 |
Talacotuzumab | IL-3RA | Human IL-3RA Antibody (Talacotuzumab, Research Use) | NBR-0124 |
Forerunner patent anti-Prominin-1 | CD133 | Human CD133 Antibody (Forerunner patent anti-Prominin-1, Research Use) | NBR-0125 |
Samalizumab | CD200 | Human CD200 Antibody (Samalizumab, Research Use) | NBR-0126 |
Janssen patent anti-CD200R1 | CD200R | Human CD200R Antibody (Janssen patent anti-CD200R1, Research Use) | NBR-0127 |
Basiliximab | CD25 / IL-1RA | Human CD25 / IL-1RA Antibody (Basiliximab, Research Use) | NBR-0128 |
Belantamab | BCMA | Human BCMA Antibody (Belantamab, Research Use) | NBR-0129 |
VIB9600 | CD32a | Human CD32a Antibody (VIB9600, Research Use) | NBR-0130 |
TTX-030 | CD39 | Human CD39 Antibody (TTX-030, Research Use) | NBR-0131 |
Bleselumab | CD40 | Human CD40 Antibody (Bleselumab, Research Use) | NBR-0132 |
Sotigalimab | CD40 | Human CD40 Antibody (Sotigalimab, Research Use) | NBR-0133 |
Dacetuzumab | CD40 | Human CD40 Antibody (Dacetuzumab, Research Use) | NBR-0134 |
FOR46 | CD46 | Human CD46 Antibody (FOR46, Research Use) | NBR-0135 |
Magrolimab | CD47 | Human CD47 Antibody (Magrolimab, Research Use) | NBR-0136 |
CC-90002 | CD47 | Human CD47 Antibody (CC-90002, Research Use) | NBR-0137 |
Alemtuzumab | CD52 | Human CD52 Antibody (Alemtuzumab, Research Use) | NBR-0138 |
Lorvotuzumab | CD56 | Human CD56 Antibody (Lorvotuzumab, Research Use) | NBR-0139 |
Genefrontier patent anti-CD69 | CD69 | Human CD69 Antibody (Genefrontier patent anti-CD69, Research Use) | NBR-0140 |
Polatuzumab | CD79b / Ig B | Human CD79b / Ig B Antibody (Polatuzumab, Research Use) | NBR-0141 |
U.California patent anti-CDCP1 | CDCP1 | Human CDCP1 Antibody (U.California patent anti-CDCP1, Research Use) | NBR-0142 |
Labetuzumab | CEA | Human CEA Antibody (Labetuzumab, Research Use) | NBR-0143 |
CM-24 | CEACAM1 | Human CEACAM1 Antibody (CM-24, Research Use) | NBR-0144 |
NEO-201 | CEACAM6 | Human CEACAM6 Antibody (NEO-201, Research Use) | NBR-0145 |
Brown U. patent anti-CHI3L1 | Chitinase3-like1 | Human Chitinase3-like1 Antibody (Brown U. patent anti-CHI3L1, Research Use) | NBR-0146 |
GSK3050002 | CK-B4 | Human CK-B4 Antibody (GSK3050002, Research Use) | NBR-0147 |
FA19-1 | CLCP1 | Human CLCP1 Antibody (FA19-1, Research Use) | NBR-0148 |
Zolbetuximab | CLDN18 | Human CLDN18 Antibody (Zolbetuximab, Research Use) | NBR-0149 |
IMAB027 | CLDN6 | Human CLDN6 Antibody (IMAB027, Research Use) | NBR-0150 |
Tepoditamab | CLEC12A | Human CLEC12A Antibody (Tepoditamab, Research Use) | NBR-0151 |
Scripps Korea patent anti-CLEC14A | CLEC14A | Human CLEC14A Antibody (Scripps Korea patent anti-CLEC14A, Research Use) | NBR-0152 |
Oxford Bio patent anti-CRTAM | CRTAM | Human CRTAM Antibody (Oxford Bio patent anti-CRTAM, Research Use) | NBR-0153 |
Cabiralizumab | CSF1R | Human CSF1R Antibody (Cabiralizumab, Research Use) | NBR-0154 |
Med. Bio. Labs patent anti-CXADR | CXADR | Human CXADR Antibody (Med. Bio. Labs patent anti-CXADR, Research Use) | NBR-0155 |
Eldelumab | CXCL10 | Human CXCL10 Antibody (Eldelumab, Research Use) | NBR-0156 |
Novimmune patent anti-CXCL9 | CXCL9 | Human CXCL9 Antibody (Novimmune patent anti-CXCL9, Research Use) | NBR-0157 |
SAR113244 | CXCR5 | Human CXCR5 Antibody (SAR113244, Research Use) | NBR-0158 |
INSERM patent anti-DC-SIGN | DC-SIGN | Human DC-SIGN Antibody (INSERM patent anti-DC-SIGN, Research Use) | NBR-0159 |
Baylor patent anti-Dectin-1 | Dectin-1 | Human Dectin-1 Antibody (Baylor patent anti-Dectin-1, Research Use) | NBR-0160 |
BHQ-880 | DKK1 | Human DKK1 Antibody (BHQ-880, Research Use) | NBR-0161 |
Demcizumab | DLL4 | Human DLL4 Antibody (Demcizumab, Research Use) | NBR-0162 |
Navicixizumab | DLL4 | Human DLL4 Antibody (Navicixizumab, Research Use) | NBR-0163 |
Abbvie patent anti-TNFRSF21 | DR6 | Human DR6 Antibody (Abbvie patent anti-TNFRSF21, Research Use) | NBR-0164 |
Citatuzumab | EPCAM | Human EPCAM Antibody (Citatuzumab, Research Use) | NBR-0165 |
Genentech patent anti-EphB2 | EphB2 | Human EphB2 Antibody (Genentech patent anti-EphB2, Research Use) | NBR-0166 |
Morphosys patent anti-EphB4 | EphB4 | Human EphB4 Antibody (Morphosys patent anti-EphB4, Research Use) | NBR-0167 |
VasGene patent anti-EphB4 | EphB4 | Human EphB4 Antibody (VasGene patent anti-EphB4, Research Use) | NBR-0168 |
Roche patent anti-Her3 / Her4 | ErbB4 | Human ErbB4 Antibody (Roche patent anti-Her3 / Her4, Research Use) | NBR-0169 |
Abbott patent anti-EPO Receptor | ErythropoietinR | Human ErythropoietinR Antibody (Abbott patent anti-EPO Receptor, Research Use) | NBR-0170 |
Sibrotuzumab | FAP | Human FAP Antibody (Sibrotuzumab, Research Use) | NBR-0171 |
LY2928057 | Ferroportin | Human Ferroportin Antibody (LY2928057, Research Use) | NBR-0172 |
Amgen patent anti-Ferroportin | Ferroportin | Human Ferroportin Antibody (Amgen patent anti-Ferroportin, Research Use) | NBR-0173 |
1A6 | FGF19 | Human FGF19 Antibody (1A6, Research Use) | NBR-0174 |
HuGAL-F2 | FGF2 | Human FGF2 Antibody (HuGAL-F2, Research Use) | NBR-0175 |
LY3076226 | FGFR3 | Human FGFR3 Antibody (LY3076226, Research Use) | NBR-0176 |
Vofatamab | FGFR3 | Human FGFR3 Antibody (Vofatamab, Research Use) | NBR-0177 |
U3-1784 | FGFR4 | Human FGFR4 Antibody (U3-1784, Research Use) | NBR-0178 |
L19-TNF | Fibronectin | Human Fibronectin Antibody (L19-TNF, Research Use) | NBR-0179 |
IMC-EB10 | FLT3 | Human FLT3 Antibody (IMC-EB10, Research Use) | NBR-0180 |
U.Toronto patent anti-FZD7 | Frizzled-7 | Human Frizzled-7 Antibody (U.Toronto patent anti-FZD7, Research Use) | NBR-0181 |
Crotedumab | GCGR | Human GCGR Antibody (Crotedumab, Research Use) | NBR-0182 |
Volagidemab | GCGR | Human GCGR Antibody (Volagidemab, Research Use) | NBR-0183 |
CSL patent anti-G-CSFR | G-CSFR | Human G-CSFR Antibody (CSL patent anti-G-CSFR, Research Use) | NBR-0184 |
Amgen patent anti-GIPR | GIPR | Human GIPR Antibody (Amgen patent anti-GIPR, Research Use) | NBR-0185 |
Ragifilimab | GITR | Human GITR Antibody (Ragifilimab, Research Use) | NBR-0186 |
Mavrilimumab | GM-CSF2RA | Human GM-CSF2RA Antibody (Mavrilimumab, Research Use) | NBR-0187 |
Regeneron patent anti-GP130 / LEPR | Gp130 | Human Gp130 Antibody (Regeneron patent anti-GP130 / LEPR, Research Use) | NBR-0188 |
KRN330 | GPA33 | Human GPA33 Antibody (KRN330, Research Use) | NBR-0189 |
Glembatumumab | GPNMB | Human GPNMB Antibody (Glembatumumab, Research Use) | NBR-0190 |
BNC101 | GPR49 | Human GPR49 Antibody (BNC101, Research Use) | NBR-0191 |
Petosemtamab | GPR49 | Human GPR49 Antibody (Petosemtamab, Research Use) | NBR-0192 |
Talquetamab | GPRC5D | Human GPRC5D Antibody (Talquetamab, Research Use) | NBR-0193 |
UCB patent anti-Gremlin-1 | Gremlin | Human Gremlin Antibody (UCB patent anti-Gremlin-1, Research Use) | NBR-0194 |
KHK patent anti-Haptoglobin | Haptoglobin | Human Haptoglobin Antibody (KHK patent anti-Haptoglobin, Research Use) | NBR-0195 |
KHK2866 | HB-EGF | Human HB-EGF Antibody (KHK2866, Research Use) | NBR-0196 |
U3-1565 | HB-EGF | Human HB-EGF Antibody (U3-1565, Research Use) | NBR-0197 |
Patritumab | HER3 | Human HER3 Antibody (Patritumab, Research Use) | NBR-0198 |
Seribantumab | HER3 | Human HER3 Antibody (Seribantumab, Research Use) | NBR-0199 |
Ficlatuzumab | HGF / SF | Human HGF / SF Antibody (Ficlatuzumab, Research Use) | NBR-0200 |
Rilotumumab | HGF / SF | Human HGF / SF Antibody (Rilotumumab, Research Use) | NBR-0201 |
Emibetuzumab | c-Met / HGFR | Human c-Met / HGFR Antibody (Emibetuzumab, Research Use) | NBR-0202 |
Vopratelimab | ICOS | Human ICOS Antibody (Vopratelimab, Research Use) | NBR-0203 |
Feladilimab | ICOS | Human ICOS Antibody (Feladilimab, Research Use) | NBR-0204 |
LIMR patent anti-IDO2 | IDO2 | Human IDO2 Antibody (LIMR patent anti-IDO2, Research Use) | NBR-0205 |
Rontalizumab | IFNA1 | Human IFNA1 Antibody (Rontalizumab, Research Use) | NBR-0206 |
Sifalimumab | IFNA1 | Human IFNA1 Antibody (Sifalimumab, Research Use) | NBR-0207 |
Xentuzumab | IGF-1 | Human IGF-1 Antibody (Xentuzumab, Research Use) | NBR-0208 |
Teprotumumab | IGF-1R | Human IGF-1R Antibody (Teprotumumab, Research Use) | NBR-0209 |
Ustekinumab | IL-12 | Human IL-12 Antibody (Ustekinumab, Research Use) | NBR-0210 |
Anrukinzumab | IL-13 | Human IL-13 Antibody (Anrukinzumab, Research Use) | NBR-0211 |
Wake Forest U. patent anti-IL-13RA2 | IL-13RA2 | Human IL-13RA2 Antibody (Wake Forest U. patent anti-IL-13RA2, Research Use) | NBR-0212 |
MOR106 | IL-17C | Human IL-17C Antibody (MOR106, Research Use) | NBR-0213 |
AMG 108 | IL-1R1 | Human IL-1R1 Antibody (AMG 108, Research Use) | NBR-0214 |
Spesolimab | IL-1RL2 | Human IL-1RL2 Antibody (Spesolimab, Research Use) | NBR-0215 |
Imsidolimab | IL-1RL2 | Human IL-1RL2 Antibody (Imsidolimab, Research Use) | NBR-0216 |
Fletikumab | IL-20 | Human IL-20 Antibody (Fletikumab, Research Use) | NBR-0217 |
Cheng Kung U. patent anti-IL-20R1 | IL-20RA | Human IL-20RA Antibody (Cheng Kung U. patent anti-IL-20R1, Research Use) | NBR-0218 |
Fezakinumab | IL-22 | Human IL-22 Antibody (Fezakinumab, Research Use) | NBR-0219 |
Guselkumab | IL-23 | Human IL-23 Antibody (Guselkumab, Research Use) | NBR-0220 |
Tildrakizumab | IL-23P19 | Human IL-23P19 Antibody (Tildrakizumab, Research Use) | NBR-0221 |
Singapore ASTR patent anti-IL-2R beta / IL-2R gamma | IL-2RB | Human IL-2RB Antibody (Singapore ASTR patent anti-IL-2R beta / IL-2R gamma , Research Use) | NBR-0222 |
Daclizumab | IL-2RA | Human IL-2RA Antibody (Daclizumab, Research Use) | NBR-0223 |
Nemolizumab | IL-31RA | Human IL-31RA Antibody (Nemolizumab, Research Use) | NBR-0224 |
Etokimab | IL-33 | Human IL-33 Antibody (Etokimab, Research Use) | NBR-0225 |
Pascolizumab | IL-4 | Human IL-4 Antibody (Pascolizumab, Research Use) | NBR-0226 |
Dupilumab | IL-4RA | Human IL-4RA Antibody (Dupilumab, Research Use) | NBR-0227 |
Mepolizumab | IL-5 | Human IL-5 Antibody (Mepolizumab, Research Use) | NBR-0228 |
Benralizumab | IL-5RA | Human IL-5RA Antibody (Benralizumab, Research Use) | NBR-0229 |
Lusvertikimab | IL-7RA | Human IL-7RA Antibody (Lusvertikimab, Research Use) | NBR-0230 |
HuMax-IL8 | IL-8 | Human IL-8 Antibody (HuMax-IL8, Research Use) | NBR-0231 |
Enokizumab | IL-9 | Human IL-9 Antibody (Enokizumab , Research Use) | NBR-0232 |
Innate patent anti-KIR2DL | KIR2DL1 | Human KIR2DL1 Antibody (Innate patent anti-KIR2DL , Research Use) | NBR-0233 |
Relatlimab | LAG3 | Human LAG3 Antibody (Relatlimab, Research Use) | NBR-0234 |
Brigham and Womens anti-LAP | LAP | Human LAP Antibody (Brigham and Womens anti-LAP, Research Use) | NBR-0235 |
Mibavademab | LEPR | Human LEPR Antibody (Mibavademab, Research Use) | NBR-0236 |
MB 311 | LeY | Human LeY Antibody (MB 311, Research Use) | NBR-0237 |
JTX-8064 | LILRB2 | Human LILRB2 Antibody (JTX-8064, Research Use) | NBR-0238 |
Simtuzumab | LOXL2 | Human LOXL2 Antibody (Simtuzumab, Research Use) | NBR-0239 |
Ontamalimab | MAdCAM-1 | Human MAdCAM-1 Antibody (Ontamalimab, Research Use) | NBR-0240 |
Refanezumab | MAG | Human MAG Antibody (Refanezumab, Research Use) | NBR-0241 |
CT Atlantic patent anti-MAGE-A3 | MAGE-A3 | Human MAGE-A3 Antibody (CT Atlantic patent anti-MAGE-A3, Research Use) | NBR-0242 |
Narsoplimab | MASP-2 | Human MASP-2 Antibody (Narsoplimab, Research Use) | NBR-0243 |
RGX-019 | MERTK | Human MERTK Antibody (RGX-019, Research Use) | NBR-0244 |
Amatuximab | Mesothelin | Human Mesothelin Antibody (Amatuximab, Research Use) | NBR-0245 |
Anetumab | Mesothelin | Human Mesothelin Antibody (Anetumab, Research Use) | NBR-0246 |
Imalumab | MIF | Human MIF Antibody (Imalumab, Research Use) | NBR-0247 |
Andecaliximab | MMP-9 | Human MMP-9 Antibody (Andecaliximab, Research Use) | NBR-0248 |
Ensituximab | MU5AC | Human MU5AC Antibody (Ensituximab, Research Use) | NBR-0249 |
Clivatuzumab | MUC1 | Human MUC1 Antibody (Clivatuzumab, Research Use) | NBR-0250 |
Oregovomab | MUC16 | Human MUC16 Antibody (Oregovomab, Research Use) | NBR-0251 |
Sofituzumab | CA125 | Human CA125 Antibody (Sofituzumab, Research Use) | NBR-0252 |
Landogrozumab | Myostatin | Human Myostatin Antibody (Landogrozumab, Research Use) | NBR-0253 |
Trevogrumab | Myostatin | Human Myostatin Antibody (Trevogrumab, Research Use) | NBR-0254 |
Fulranumab | NGF | Human NGF Antibody (Fulranumab, Research Use) | NBR-0255 |
Tanezumab | NGF | Human NGF Antibody (Tanezumab, Research Use) | NBR-0256 |
Monalizumab | NKG2A | Human NKG2A Antibody (Monalizumab, Research Use) | NBR-0257 |
Ozanezumab | Nogo-A | Human Nogo-A Antibody (Ozanezumab, Research Use) | NBR-0258 |
Brontictuzumab | Notch1 | Human Notch1 Antibody (Brontictuzumab, Research Use) | NBR-0259 |
Vesencumab | NRP1 | Human NRP1 Antibody (Vesencumab, Research Use) | NBR-0260 |
Tavolixizumab | OX40 | Human OX40 Antibody (Tavolixizumab, Research Use) | NBR-0261 |
Oxelumab | OX40L | Human OX40L Antibody (Oxelumab, Research Use) | NBR-0262 |
Alirocumab | PCSK9 | Human PCSK9 Antibody (Alirocumab, Research Use) | NBR-0263 |
Thrombogenics patent anti-PDGF-C | PDGFC | Human PDGFC Antibody (Thrombogenics patent anti-PDGF-C, Research Use) | NBR-0264 |
Tovetumab | PDGFRA | Human PDGFRA Antibody (Tovetumab, Research Use) | NBR-0265 |
Olaratumab | PDGFRA | Human PDGFRA Antibody (Olaratumab, Research Use) | NBR-0266 |
Rinucumab | PDGFRB | Human PDGFRB Antibody (Rinucumab, Research Use) | NBR-0267 |
Novo Nordisk patent anti-PGLYRP1 | PGLYRP1 | Human PGLYRP1 Antibody (Novo Nordisk patent anti-PGLYRP1, Research Use) | NBR-0268 |
Diaccurate patent anti-sPLA2-GIB | PLA2G1B | Human PLA2G1B Antibody (Diaccurate patent anti-sPLA2-GIB, Research Use) | NBR-0269 |
Eureka patent anti-PRAME | PRAME | Human PRAME Antibody (Eureka patent anti-PRAME, Research Use) | NBR-0270 |
AGS-1C4D4 | PSCA | Human PSCA Antibody (AGS-1C4D4, Research Use) | NBR-0271 |
GSK4381562 | PVRIG | Human PVRIG Antibody (GSK4381562, Research Use) | NBR-0272 |
COM701 | PVRIG | Human PVRIG Antibody (COM701, Research Use) | NBR-0273 |
XT-M4 | RAGE | Human RAGE Antibody (XT-M4, Research Use) | NBR-0274 |
Denosumab | RANKL | Human RANKL Antibody (Denosumab, Research Use) | NBR-0275 |
Narnatumab | RON | Human RON Antibody (Narnatumab, Research Use) | NBR-0276 |
Oncomed patent anti-RSPO1 | RSPO1 | Human RSPO1 Antibody (Oncomed patent anti-RSPO1, Research Use) | NBR-0277 |
Rosmantuzumab | RSPO3 | Human RSPO3 Antibody (Rosmantuzumab, Research Use) | NBR-0278 |
Setrusumab | Sclerostin | Human Sclerostin Antibody (Setrusumab, Research Use) | NBR-0279 |
Romosozumab | Sclerostin | Human Sclerostin Antibody (Romosozumab, Research Use) | NBR-0280 |
Pepinemab | SEMA4D | Human SEMA4D Antibody (Pepinemab, Research Use) | NBR-0281 |
Hospital for Sick Children patent anti-SIRPA | SIRPA | Human SIRPA Antibody (Hospital for Sick Children patent anti-SIRPA, Research Use) | NBR-0282 |
KWAR23 | SIRPG | Human SIRPG Antibody (KWAR23, Research Use) | NBR-0283 |
Bexmarilimab | STAB1 | Human STAB1 Antibody (Bexmarilimab, Research Use) | NBR-0284 |
Vandortuzumab | STEAP1 | Human STEAP1 Antibody (Vandortuzumab, Research Use) | NBR-0285 |
Indatuximab | Syndecan-1 | Human Syndecan-1 Antibody (Indatuximab, Research Use) | NBR-0286 |
Gosuranemab | Tau | Human Tau Antibody (Gosuranemab, Research Use) | NBR-0287 |
Semorinemab | Tau | Human Tau Antibody (Semorinemab, Research Use) | NBR-0288 |
Tisotumab | TF | Human TF Antibody (Tisotumab, Research Use) | NBR-0289 |
SRK181 | TGFb | Human TGFb Antibody (SRK181, Research Use) | NBR-0290 |
M7824 | TGFb | Human TGFb Antibody (M7824, Research Use) | NBR-0291 |
Sabatolimab | TIM-3 / HAVCR2 | Human TIM-3 / HAVCR2 Antibody (Sabatolimab, Research Use) | NBR-0292 |
Tomaralimab | TLR2 | Human TLR2 Antibody (Tomaralimab, Research Use) | NBR-0293 |
C1068 | TLR3 | Human TLR3 Antibody (C1068, Research Use) | NBR-0294 |
Mapatumumab | TRAIL-R1 | Human TRAIL-R1 Antibody (Mapatumumab, Research Use) | NBR-0295 |
GBR 900 | TrkA | Human TrkA Antibody (GBR 900, Research Use) | NBR-0296 |
Sacituzumab | TROP-2 | Human TROP-2 Antibody (Sacituzumab, Research Use) | NBR-0297 |
Enavatuzumab | TWEAKR | Human TWEAKR Antibody (Enavatuzumab, Research Use) | NBR-0298 |
ELB031 | TYRO3 | Human TYRO3 Antibody (ELB031, Research Use) | NBR-0299 |
Timolumab | VAP-1 | Human VAP-1 Antibody (Timolumab, Research Use) | NBR-0300 |
Icrucumab | FLT1 / VEGFR1 | Human FLT1 / VEGFR1 Antibody (Icrucumab, Research Use) | NBR-0301 |
DS-6000a | CDH6 | Human CDH6 Antibody (DS-6000a, Research Use) | NBR-0302 |
Tabituximab | Frizzled-10 | Human Frizzled-10 Antibody (Tabituximab, Research Use) | NBR-0303 |
Itolizumab | CD6 | Human CD6 Antibody (Itolizumab, Research Use) | NBR-0304 |
Asclepius Technology patent anti-Robo1 CAR | Robo1 | Human Robo1 Antibody (Asclepius Technology patent anti-Robo1 CAR, Research Use) | NBR-0305 |
Murlentamab | AMHR2 | Human AMHR2 Antibody (Murlentamab, Research Use) | NBR-0306 |
Idactamab | ASCT2 | Human ASCT2 Antibody (Idactamab, Research Use) | NBR-0307 |
Carotuximab | CD105 | Human CD105 Antibody (Carotuximab, Research Use) | NBR-0308 |
Regeneron patent anti-CD48 | CD48 | Human CD48 Antibody (Regeneron patent anti-CD48, Research Use) | NBR-0309 |
SC-005 | Melanotransferrin | Human Melanotransferrin Antibody (SC-005, Research Use) | NBR-0310 |
Ianalumab | BAFFR | Human BAFFR Antibody (Ianalumab, Research Use) | NBR-0311 |
GFB-024 | CB1 | Human CB1 Antibody (GFB-024, Research Use) | NBR-0312 |
Erenumab | CGRPR | Human CGRPR Antibody (Erenumab, Research Use) | NBR-0313 |
Garadacimab | Factor XII | Human Factor XII Antibody (Garadacimab, Research Use) | NBR-0314 |
Burosumab | FGF23 | Human FGF23 Antibody (Burosumab, Research Use) | NBR-0315 |
BMS-986012 | Fucosyl GM1 | Human Fucosyl GM1 Antibody (BMS-986012, Research Use) | NBR-0316 |
Anifrolumab | IFNAR-1 | Human IFNAR-1 Antibody (Anifrolumab, Research Use) | NBR-0317 |
ARGX-112 | IL-22RA | Human IL-22RA Antibody (ARGX-112, Research Use) | NBR-0318 |
Daxdilimab | ILT7 | Human ILT7 Antibody (Daxdilimab, Research Use) | NBR-0319 |
Lanadelumab | Kallikrein | Human Kallikrein Antibody (Lanadelumab, Research Use) | NBR-0320 |
Orticumab | oxLDL | Human oxLDL Antibody ( Orticumab, Research Use) | NBR-0321 |
CTX-2026 | Butyrophilin | Human Butyrophilin Antibody (CTX-2026, Research Use) | NBR-0322 |
ARGX-117 | C2 | Human C2 Antibody (ARGX-117, Research Use) | NBR-0323 |
NGM621 | C3 | Human C3 Antibody (NGM621, Research Use) | NBR-0324 |
Atibuclimab | CD14 | Human CD14 Antibody (Atibuclimab, Research Use) | NBR-0325 |
AB-16B5 | Clusterin | Human Clusterin Antibody (AB-16B5, Research Use) | NBR-0326 |
CSL324 | G-CSF | Human G-CSF Antibody (CSL324, Research Use) | NBR-0327 |
DS-6157 | GPR20 | Human GPR20 Antibody (DS-6157, Research Use) | NBR-0328 |
OS2966 | Integrin B1 | Human Integrin B1 Antibody (OS2966, Research Use) | NBR-0329 |
NP137 | Netrin 1 | Human Netrin 1 Antibody (NP137, Research Use) | NBR-0330 |
Bavituximab | Phosphatidylserine | Human Phosphatidylserine Antibody ( Bavituximab, Research Use) | NBR-0331 |
CSL346 | VEGFB | Human VEGFB Antibody (CSL346, Research Use) | NBR-0332 |
Garetosmab | Activin A | Human Activin A Antibody (Garetosmab, Research Use) | NBR-0333 |
Enibarcimab | Adrenomedullin | Human Adrenomedullin Antibody (Enibarcimab, Research Use) | NBR-0334 |
ANX005 | C1q | Human C1q Antibody (ANX005, Research Use) | NBR-0335 |
CSL311 | CSF2RB | Human CSF2RB Antibody (CSL311, Research Use) | NBR-0336 |
NGM120 | GFRAL | Human GFRAL Antibody (NGM120, Research Use) | NBR-0337 |
Glenzocimab | GPVI | Human GPVI Antibody (Glenzocimab, Research Use) | NBR-0338 |
ATH3G10 | Phosphorylcholine | Human Phosphorylcholine Antibody (ATH3G10, Research Use) | NBR-0339 |
M6495 | ADAMTS5 | Human ADAMTS5 Antibody (M6495, Research Use) | NBR-0340 |
MK-6105 | IL-13RA1 | Human IL-13RA1 Antibody (MK-6105, Research Use) | NBR-0341 |
Bapotulimab | ILDR2 | Human ILDR2 Antibody (Bapotulimab, Research Use) | NBR-0342 |
Indusatumab | GCC | Human GCC Antibody (Indusatumab, Research Use) | NBR-0343 |
STX-100 | Integrin AV & B6 | Human Integrin AV & B6 Antibody (STX-100, Research Use) | NBR-0344 |
Milatuzumab | MHC | Human MHC Antibody (Milatuzumab, Research Use) | NBR-0345 |
Lifastuzumab | NaPi2b | Human NaPi2b Antibody ( Lifastuzumab, Research Use) | NBR-0346 |
MGD007 | A33 | Human A33 Antibody (MGD007, Research Use) | NBR-0347 |
Apamistamab | CD45 | Human CD45 Antibody (Apamistamab, Research Use) | NBR-0348 |
Emicizumab | Factor IX | Human Factor IX Antibody (Emicizumab, Research Use) | NBR-0349 |
Vedolizumab | Integrin A4 & B7 | Human Integrin A4 & B7 Antibody ( Vedolizumab, Research Use) | NBR-0350 |
MVT-5873 | Sialyl-Lewis A | Human Sialyl-Lewis A Antibody (MVT-5873, Research Use) | NBR-0351 |
INSERM patent anti-vWF | vWF | Human vWF Antibody (INSERM patent anti-vWF, Research Use) | NBR-0352 |
Genzyme patent anti-CXCR3 | CXCR3 | Human CXCR3 Antibody (Genzyme patent anti-CXCR3, Research Use) | NBR-0353 |
TA136 | TPOR | Human TPOR Antibody (TA136, Research Use) | NBR-0354 |
Genentech patent anti-Tryptase Beta 1 | TPSAB1 | Human TPSAB1 Antibody (Genentech patent anti-Tryptase Beta 1, Research Use) | NBR-0355 |
Genentech patent anti-Bv8 | Bv8 | Human Bv8 Antibody (Genentech patent anti-Bv8, Research Use) | NBR-0356 |
M116 | CCL17 | Human CCL17 Antibody (M116, Research Use) | NBR-0357 |
KHK patent anti-CRTH2 | CRTh2 | Human CRTh2 Antibody (KHK patent anti-CRTH2, Research Use) | NBR-0358 |
Cureab patent anti-GP73 | GP73 | Human GP73 Antibody (Cureab patent anti-GP73, Research Use) | NBR-0359 |
Regeneron patent anti-GREM1 | GREM1 | Human GREM1 Antibody (Regeneron patent anti-GREM1, Research Use) | NBR-0360 |
Erlizumab | Integrin B2 | Human Integrin B2 Antibody (Erlizumab, Research Use) | NBR-0361 |
Abbott patent anti-NGR | NGR | Human NGR Antibody (Abbott patent anti-NGR, Research Use) | NBR-0362 |
Lilly patent anti-PACAP | PACAP-38 | Human PACAP-38 Antibody (Lilly patent anti-PACAP, Research Use) | NBR-0363 |
Novelmed patent anti-Properdin | Properdin | Human Properdin Antibody (Novelmed patent anti-Properdin, Research Use) | NBR-0364 |
DISC-0974 | RGM C | Human RGM C Antibody (DISC-0974, Research Use) | NBR-0365 |
Genentech patent anti-TAT226 | TAT226 | Human TAT226 Antibody (Genentech patent anti-TAT226, Research Use) | NBR-0366 |
Regeneron patent anti-TMPRSS2 | TMPRSS2 | Human TMPRSS2 Antibody (Regeneron patent anti-TMPRSS2 , Research Use) | NBR-0367 |
Genentech patent anti-HGFA | HGFA | Human HGFA Antibody (Genentech patent anti-HGFA , Research Use) | NBR-0368 |
Chugai patent anti-HLA-DQ2 | HLA-DQ2 | Human HLA-DQ2 Antibody (Chugai patent anti-HLA-DQ2, Research Use) | NBR-0369 |
Genentech patent anti-KLK5 | KLK5 | Human KLK5 Antibody (Genentech patent anti-KLK5, Research Use) | NBR-0370 |
Amgen patent anti-ORAI1 | ORAI1 | Human ORAI1 Antibody (Amgen patent anti-ORAI1, Research Use) | NBR-0371 |
Sanofi patent anti-PAI-1 | PAI-1 | Human PAI-1 Antibody (Sanofi patent anti-PAI-1, Research Use) | NBR-0372 |
Novartis patent anti-PAR1 | PAR1 | Human PAR1 Antibody (Novartis patent anti-PAR1, Research Use) | NBR-0373 |
U.Penn. patent anti-PF4 | PF4 / CXCL4 | Human PF4 / CXCL4 Antibody (U.Penn. patent anti-PF4, Research Use) | NBR-0374 |
Multiple seq-one in animal | PROKR1 | Human PROKR1 Antibody (Multiple seq-one in animal, Research Use) | NBR-0375 |
Numab patent anti-HSA | Serum Albumin | Human Serum Albumin Antibody (Numab patent anti-HSA, Research Use) | NBR-0376 |
Genentech patent anti-STOP-1 | STOP-1 | Human STOP-1 Antibody (Genentech patent anti-STOP-1, Research Use) | NBR-0377 |
Janssen patent anti-TMEFF2 | TENB2 | Human TENB2 Antibody (Janssen patent anti-TMEFF2, Research Use) | NBR-0378 |
Regeneron patent anti-TIE-2 | TIE-2 | Human TIE-2 Antibody (Regeneron patent anti-TIE-2, Research Use) | NBR-0379 |
Novartis patent anti-TMEM16A | TMEM16A | Human TMEM16A Antibody (Novartis patent anti-TMEM16A , Research Use) | NBR-0380 |
Genentech patent anti-Polyubiquitin | Polyubiquitin | Human Polyubiquitin Antibody (Genentech patent anti-Polyubiquitin, Research Use) | NBR-0381 |
Duke anti-NAv1.7 | Nav1.7 | Human Nav1.7 Antibody (Duke anti-NAv1.7, Research Use) | NBR-0382 |
Genentech patent anti-Integrin β7 | Integrin B7 | Human Integrin B7 Antibody (Genentech patent anti-Integrin β7, Research Use) | NBR-0383 |
Genentech patent anti-Jagged1 | JAG1 | Human JAG1 Antibody (Genentech patent anti-Jagged1, Research Use) | NBR-0384 |
Regeneron patent anti-APLNR | APLNR | Human APLNR Antibody (Regeneron patent anti-APLNR, Research Use) | NBR-0385 |
Immunomedics patent anti-Histone H2B | Histone H2B | Human Histone H2B Antibody (Immunomedics patent anti-Histone H2B, Research Use) | NBR-0386 |
Immunomedics patent anti-Histone H3 | Histone H3 | Human Histone H3 Antibody (Immunomedics patent anti-Histone H3, Research Use) | NBR-0387 |
Immunomedics patent anti-Histone H4 | Histone H4 | Human Histone H4 Antibody (Immunomedics patent anti-Histone H4, Research Use) | NBR-0388 |
19G9 | RG1 | Human RG1 Antibody (19G9, Research Use) | NBR-0389 |
Regeneron patent anti-ANGPTL8 | ANGPTL8 | Human ANGPTL8 Antibody (Regeneron patent anti-ANGPTL8, Research Use) | NBR-0390 |
Lilly patent anti-Pan-ELR+ | CXC-ELR | Human CXC-ELR Antibody (Lilly patent anti-Pan-ELR+, Research Use) | NBR-0391 |
FHTR2163 | HtrA1 | Human HtrA1 Antibody (FHTR2163, Research Use) | NBR-0392 |
Bayer patent anti-TIMP-1 | TIMP1 | Human TIMP1 Antibody (Bayer patent anti-TIMP-1, Research Use) | NBR-0393 |
PF-06263507 | TPBG | Human TPBG Antibody (PF-06263507, Research Use) | NBR-0394 |
OR2805 | CD163 | Human CD163 Antibody (OR2805, Research Use) | NBR-0395 |
Canakinumab | IL-1B | Human IL-1B Antibody (Canakinumab, Research Use) | NBR-0396 |
Lulizumab | CD28 | Human CD28 Antibody (Lulizumab, Research Use) | NBR-0397 |
RG7841 | Ly6E | Human Ly6E Antibody (RG7841, Research Use) | NBR-0398 |
CRX-014 | TIM-1 | Human TIM-1 Antibody (CRX-014, Research Use) | NBR-0399 |
OBI-833 | Globo H | Human Globo H Antibody (OBI-833, Research Use) | NBR-0400 |
ADCT-901 | KAAG1 | Human KAAG1 Antibody (ADCT-901, Research Use) | NBR-0401 |
KHK2898 | CD98 | Human CD98 Antibody (KHK2898, Research Use) | NBR-0402 |
ATN-658 | uPAR | Human uPAR Antibody (ATN-658, Research Use) | NBR-0403 |
LIV-1205 | DLK-1 | Human DLK-1 Antibody (LIV-1205, Research Use) | NBR-0404 |
Ontuxizumab | Endosialin | Human Endosialin Antibody (Ontuxizumab, Research Use) | NBR-0405 |
Midwestern U. patent anti-ASPH | HAAH | Human HAAH Antibody (Midwestern U. patent anti-ASPH, Research Use) | NBR-0406 |
Oxford Bio patent anti-Matriptase | Matriptase | Human Matriptase Antibody (Oxford Bio patent anti-Matriptase, Research Use) | NBR-0407 |
Copenhagen Rigshospitalet patent anti-uPARAP | MRC2 | Human MRC2 Antibody (Copenhagen Rigshospitalet patent anti-uPARAP, Research Use) | NBR-0408 |
AG02-ADC | PTGFRN | Human PTGFRN Antibody (AG02-ADC, Research Use) | NBR-0409 |
Agensys patent anti-158P1D7 | 158P1D7 | Human 158P1D7 Antibody (Agensys patent anti-158P1D7, Research Use) | NBR-0410 |
Centrose patent anti-dysadherin | dysadherin | Human dysadherin Antibody (Centrose patent anti-dysadherin, Research Use) | NBR-0411 |
Bluefin patent anti-TMEFF1 | TMEFF1 | Human TMEFF1 Antibody (Bluefin patent anti-TMEFF1, Research Use) | NBR-0412 |
Regeneron patent anti-RET | c-RET | Human c-RET Antibody (Regeneron patent anti-RET, Research Use) | NBR-0413 |
Cantuzumab | C242 | Human C242 Antibody (Cantuzumab, Research Use) | NBR-0414 |
Tamrintamab | DPEP3 | Human DPEP3 Antibody (Tamrintamab, Research Use) | NBR-0415 |
Bivatuzumab | CD44v6 | Human CD44v6 Antibody (Bivatuzumab, Research Use) | NBR-0416 |
abituzumab | Integrin AV | Human Integrin AV Antibody ( abituzumab, Research Use) | NBR-0417 |
Minomic patent anti-Glypican 1 | Glypican 1 | Human Glypican 1 Antibody (Minomic patent anti-Glypican 1, Research Use) | NBR-0418 |
Scripps patent anti-CD11a | Integrin A11 | Human Integrin A11 Antibody (Scripps patent anti-CD11a, Research Use) | NBR-0419 |
GlycoNex patent anti-Lewis Y / B | Lewis Y / B antigen | Human Lewis Y / B antigen Antibody (GlycoNex patent anti-Lewis Y / B , Research Use) | NBR-0420 |
Metuzumab | BSG2 | Human BSG2 Antibody (Metuzumab, Research Use) | NBR-0421 |
F16-IL2 | Tenascin C | Human Tenascin C Antibody (F16-IL2, Research Use) | NBR-0422 |
INSERM patent anti-Glycophorin A | Glycophorin A | Human Glycophorin A Antibody (INSERM patent anti-Glycophorin A, Research Use) | NBR-0423 |
Ecromeximab | GD3 | Human GD3 Antibody (Ecromeximab, Research Use) | NBR-0424 |
PF-03732010 | P-cadherin | Human P-cadherin Antibody ( PF-03732010, Research Use) | NBR-0425 |
Rolinsatamab | PRLR | Human PRLR Antibody (Rolinsatamab, Research Use) | NBR-0426 |
Cevostamab | IRTA2 | Human IRTA2 Antibody (Cevostamab, Research Use) | NBR-0427 |
DEDN6526A | ETB-R | Human ETB-R Antibody (DEDN6526A, Research Use) | NBR-0428 |
Samrotamab | LFL2 | Human LFL2 Antibody (Samrotamab, Research Use) | NBR-0429 |
ASG-5ME | SLC44A4 | Human SLC44A4 Antibody (ASG-5ME, Research Use) | NBR-0430 |
Sirtratumab | SLITRK6 | Human SLITRK6 Antibody (Sirtratumab, Research Use) | NBR-0431 |
SAR428926 | LAMP1 | Human LAMP1 Antibody ( SAR428926, Research Use) | NBR-0432 |
PF-06647263 | EFNA4 | Human EFNA4 Antibody (PF-06647263, Research Use) | NBR-0433 |
Cusatuzumab | CD27L / CD70 | Human CD27L / CD70 Antibody (Cusatuzumab, Research Use) | NBR-0434 |
CDX-0158 | c-Kit | Human c-Kit Antibody (CDX-0158, Research Use) | NBR-0435 |
Tarextumab | Notch3 | Human Notch3 Antibody (Tarextumab, Research Use) | NBR-0436 |
SGN-CD352A | SLAMF6 | Human SLAMF6 Antibody (SGN-CD352A, Research Use) | NBR-0437 |
Lupartumab | C4.4a | Human C4.4a Antibody (Lupartumab, Research Use) | NBR-0438 |
IMMU-114 | HLA-DR | Human HLA-DR Antibody (IMMU-114, Research Use) | NBR-0439 |
Blinatumomab | CD3 | Human CD3 Antibody (Blinatumomab, Research Use) | NBR-0440 |
Secukinumab | IL-17 | Human IL-17 Antibody (Secukinumab, Research Use) | NBR-0441 |
Tralokinumab | IL-13 | Human IL-13 Antibody (Tralokinumab, Research Use) | NBR-0442 |
Zanolimumab | CD4 | Human CD4 Antibody (Zanolimumab, Research Use) | NBR-0443 |
Forerunner patent anti-DSG3 | DSG3 | Human DSG3 Antibody (Forerunner patent anti-DSG3, Research Use) | NBR-0444 |
AFM13 | FCgR3A | Human FCgR3A Antibody ( AFM13, Research Use) | NBR-0445 |
JNJ-69086420 | KLK2 | Human KLK2 Antibody (JNJ-69086420, Research Use) | NBR-0446 |
K1-70 | TSHR | Human TSHR Antibody (K1-70, Research Use) | NBR-0447 |
Mellitus patent anti-CD59 | CD59 | Human CD59 Antibody (Mellitus patent anti-CD59, Research Use) | NBR-0448 |
Zymogenetics patent anti-BCMA / TACI | BCMA & TACI | Human BCMA & TACI Antibody (Zymogenetics patent anti-BCMA / TACI, Research Use) | NBR-0449 |
Teplizumab | CD3e | Human CD3e Antibody (Teplizumab, Research Use) | NBR-0450 |
Argenx patent anti-MuSK | MUSK | Human MUSK Antibody (Argenx patent anti-MuSK, Research Use) | NBR-0451 |
CLN-619 | MICA | Human MICA Antibody (CLN-619, Research Use) | NBR-0452 |
CDH17_A4 | CDH17 | Human CDH17 Antibody (CDH17_A4, Research Use) | NBR-0453 |
Eculizumab | C5 | Human C5 Antibody (Eculizumab, Research Use) | NBR-0454 |
PAR650097 | PAR-2 | Human PAR-2 Antibody (PAR650097, Research Use) | NBR-0455 |
Nadecnemab | GFRA3 | Human GFRA3 Antibody (Nadecnemab, Research Use) | NBR-0456 |
Atrosimab | TNFRSF1A | Human TNFRSF1A Antibody (Atrosimab, Research Use) | NBR-0457 |
PY159 | TREM-1 | Human TREM-1 Antibody (PY159, Research Use) | NBR-0458 |
RG6125 | Cadherin-11 | Human Cadherin-11 Antibody (RG6125, Research Use) | NBR-0459 |
Wuhan U. patent anti-Nav1.9 | Nav1.9 | Human Nav1.9 Antibody (Wuhan U. patent anti-Nav1.9, Research Use) | NBR-0460 |
U.Tokyo patent anti-TLR7 | TLR7 | Human TLR7 Antibody (U.Tokyo patent anti-TLR7, Research Use) | NBR-0461 |
Leronlimab | CCR5 | Human CCR5 Antibody (Leronlimab, Research Use) | NBR-0462 |
Drozitumab | DR5 / TRAILR2 | Human DR5 / TRAILR2 Antibody (Drozitumab, Research Use) | NBR-0463 |
MEN1309 | LY75 | Human LY75 / CD205 Antibody (MEN1309, Research Use) | NBR-0464 |
Adalimumab | TNFSF2 | Human TNFSF2 / TNFa Antibody (Adalimumab, Research Use) | NBR-0465 |
HKT288 | CDH6 | Human CDH6 / K-Cadherin Antibody (HKT288, Research Use) | NBR-0466 |
Genefrontier patent anti-CD69 | CD69 | Human CD69 Antibody (Genefrontier patent anti-CD69, Research Use) | NBR-0467 |
Scripps Korea patent anti-CLEC14A | CLEC14A | Human CLEC14A Antibody (Scripps Korea patent anti-CLEC14A, Research Use) | NBR-0468 |
Oxford Bio patent anti-CRTAM | CRTAM | Human CRTAM / CD355 Antibody (Oxford Bio patent anti-CRTAM, Research Use) | NBR-0469 |
Med. Bio. Labs patent anti-CXADR | CXADR | Human CXADR Antibody (Med. Bio. Labs patent anti-CXADR, Research Use) | NBR-0470 |
Novimmune patent anti-CXCL9 | CXCL9 | Human CXCL9 Antibody (Novimmune patent anti-CXCL9, Research Use) | NBR-0471 |
INSERM patent anti-DC-SIGN | CD209 | Human DC-SIGN / CD209 Antibody (INSERM patent anti-DC-SIGN, Research Use) | NBR-0472 |
Amgen patent anti-Ferroportin | SLC40A1 | Human SLC40A1 Antibody (Amgen patent anti-Ferroportin, Research Use) | NBR-0473 |
CSL patent anti-G-CSFR | CSF3R | Human CSF3R / G-CSFR Antibody (CSL patent anti-G-CSFR, Research Use) | NBR-0474 |
KHK patent anti-Haptoglobin | Haptoglobin | Human Haptoglobin Antibody (KHK patent anti-Haptoglobin, Research Use) | NBR-0475 |
Wake Forest U. patent anti-IL-13RA2 | IL-13Ra2 | Human IL-13Ra2 / CD213a2 Antibody (Wake Forest U. patent anti-IL-13RA2, Research Use) | NBR-0476 |
Cheng Kung U. patent anti-IL-20R1 | IL20RA | Human IL-20Ra Antibody (Cheng Kung U. patent anti-IL-20R1, Research Use) | NBR-0477 |
Enokizumab | IL-9 | Human IL-9 Antibody (Enokizumab, Research Use) | NBR-0478 |
Innate patent anti-KIR2DL | KIR2DL1 | Human KIR2DL1 / CD158a Antibody (Innate patent anti-KIR2DL, Research Use) | NBR-0479 |
Novo Nordisk patent anti-PGLYRP1 | PGLYRP1 | Human PGLYRP1 / PGRP-S Antibody (Novo Nordisk patent anti-PGLYRP1, Research Use) | NBR-0480 |
Diaccurate patent anti-sPLA2-GIB | PLA2G1B | Human PLA2G1B Antibody (Diaccurate patent anti-sPLA2-GIB, Research Use) | NBR-0481 |
Oncomed patent anti-RSPO1 | RSPO1 | Human RSPO1 Antibody (Oncomed patent anti-RSPO1, Research Use) | NBR-0482 |
Mapatumumab | TNFRSF10A | Human TNFRSF10A / TRAILR1 / CD261 Antibody (Mapatumumab, Research Use) | NBR-0483 |
Regeneron patent anti-CD48 | CD48 | Human CD48 Antibody (Regeneron patent anti-CD48, Research Use) | NBR-0484 |
Regeneron patent anti-PROKR1 | PROKR1 | Human GPR73 / PROKR1 Antibody (Regeneron patent anti-PROKR1, Research Use) | NBR-0485 |
Genentech patent anti-Polyubiquitin | UBB | Human Polyubiquitin Antibody (Genentech patent anti-Polyubiquitin, Research Use) | NBR-0486 |
SAR428926 | LAMP1 | Human LAMP1 / CD107a Antibody (SAR428926, Research Use) | NBR-0487 |
Forerunner patent anti-DSG3 | DSG3 | Human DSG3 Antibody (Forerunner patent anti-DSG3, Research Use) | NBR-0488 |
AFM13 | FcgR3a | Human FcgR3a / CD16a Antibody (AFM13, Research Use) | NBR-0489 |
Mellitus patent anti-CD59 | CD59 | Human CD59 Antibody (Mellitus patent anti-CD59, Research Use) | NBR-0490 |
Selicrelumab | CD40 | Human TNFRSF5 / CD40 Antibody (Selicrelumab, Research Use) | NBR-0491 |
Domagrozumab | GDF8 | Human GDF8 / Myostatin Antibody (Domagrozumab, Research Use) | NBR-0492 |
Abrilumab | ITGA4 & ITGB7 | Human Integrin a4b7 (ITGA4 & ITGB7) Antibody (Abrilumab, Research Use) | NBR-0493 |
Amlitelimab | TNFSF4 | Human TNFSF4 / OX40L / CD252 Antibody (Amlitelimab, Research Use) | NBR-0494 |
Abagovomab | MUC16 | Human MUC16 Antibody (Abagovomab, Research Use) | NBR-0495 |
Birtamimab | SAA1 | Human Amyloid Alpha Antibody (Birtamimab, Research Use) | NBR-0496 |
Aducanumab | APP | Human Amyloid Beta Antibody (Aducanumab, Research Use) | NBR-0497 |
Abbott patent anti-Flt1 | VEGFR1 | Human VEGFR1 / FLT1 Antibody (Abbott patent anti-Flt1, Research Use) | NBR-0498 |
Crenezumab | APP | Human Amyloid Beta Antibody (Crenezumab, Research Use) | NBR-0499 |
DLX212 | APP | Human Amyloid Beta Antibody (DLX212, Research Use) | NBR-0500 |
Acceleron patent anti-ActRIIB | ACVR2B | Human ACVR2B Antibody (Acceleron patent anti-ActRIIB, Research Use) | NBR-0501 |
Gantenerumab | APP | Human Amyloid Beta Antibody (Gantenerumab, Research Use) | NBR-0502 |
Actoxumab | N/A | Human Cdiff Toxin A Antibody (Actoxumab, Research Use) | NBR-0503 |
GSK 933776 | APP | Human Amyloid Beta Antibody (GSK 933776, Research Use) | NBR-0504 |
Ajinomoto patent anti-vWF | vWF | Human vWF Antibody (Ajinomoto patent anti-vWF, Research Use) | NBR-0505 |
Alomfilimab | ICOS | Human ICOS / CD278 Antibody (Alomfilimab, Research Use) | NBR-0506 |
Amgen patent anti-beta amyloid | APP | Human Amyloid Beta Antibody (Amgen patent anti-beta amyloid, Research Use) | NBR-0507 |
MEDI3617 | ANGPT2 | Human ANGPT2 Antibody (MEDI3617, Research Use) | NBR-0508 |
Apitegromab | GDF8 | Human GDF8 / Myostatin Antibody (Apitegromab, Research Use) | NBR-0509 |
Zansecimab | ANGPT2 | Human ANGPT2 Antibody (Zansecimab, Research Use) | NBR-0510 |
Nanyang Tech.U. patent anti-ANGPTL4 | ANGPTL4 | Human ANGPTL4 Antibody (Nanyang Tech.U. patent anti-ANGPTL4, Research Use) | NBR-0511 |
Astegolimab | IL-1RL1 | Human IL-1RL1 / ST2 / IL-33R Antibody (Astegolimab, Research Use) | NBR-0512 |
Avdoralimab | C5AR1 | Human Complement C5aR1 Antibody (Avdoralimab, Research Use) | NBR-0513 |
Aveo anti-RON | MST1R | Human MSPR / RON / CD136 Antibody (Aveo anti-RON, Research Use) | NBR-0514 |
MipasetamAb | AXL | Human AXL / UFO Antibody (MipasetamAb, Research Use) | NBR-0515 |
Adebrelimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Adebrelimab, Research Use) | NBR-0516 |
Batoclimab | FCGRT | Human FcRn (FCGRT & B2M) Antibody (Batoclimab, Research Use) | NBR-0517 |
Baylor patent anti-IFN alpha | IFNa1 | Human IFNa1 Antibody (Baylor patent anti-IFN alpha, Research Use) | NBR-0518 |
Garivulimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Garivulimab, Research Use) | NBR-0519 |
Befovacimab | TFPI | Human TFPI Antibody (Befovacimab, Research Use) | NBR-0520 |
Manelimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Manelimab, Research Use) | NBR-0521 |
Begelomab | DPP4 | Human DPP4 / CD26 Antibody (Begelomab, Research Use) | NBR-0522 |
Pacmilimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Pacmilimab, Research Use) | NBR-0523 |
Sudubrilimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Sudubrilimab, Research Use) | NBR-0524 |
Sugemalimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Sugemalimab, Research Use) | NBR-0525 |
Prezalumab | ICOSLG | Human B7-H2 / ICOSL / CD275 Antibody (Prezalumab, Research Use) | NBR-0526 |
Trellis patent anti-B7-H3 | CD276 | Human B7-H3 / CD276 Antibody (Trellis patent anti-B7-H3, Research Use) | NBR-0527 |
Millennium patent anti-B7-H4 | VTCN1 | Human B7-H4 / VTCN1 Antibody (Millennium patent anti-B7-H4, Research Use) | NBR-0528 |
Genentech anti-BACE1 | BACE1 | Human BACE1 Antibody (Genentech anti-BACE1, Research Use) | NBR-0529 |
Blosozumab | SOST | Human SOST / Sclerostin Antibody (Blosozumab, Research Use) | NBR-0530 |
Bococizumab | PCSK9 | Human PCSK9 Antibody (Bococizumab, Research Use) | NBR-0531 |
Boehringer anti-PCSK9 | PCSK9 | Human PCSK9 Antibody (Boehringer anti-PCSK9, Research Use) | NBR-0532 |
Eptinezumab | CALCA | Human CALCA / CGRP Antibody (Eptinezumab, Research Use) | NBR-0533 |
Fremanezumab | CALCA | Human CALCA / CGRP Antibody (Fremanezumab, Research Use) | NBR-0534 |
Galcanezumab | CALCA | Human CALCA / CGRP Antibody (Galcanezumab, Research Use) | NBR-0535 |
Brigham and Women's patent anti-ABCB5 | ABCB5 | Human ABCB5 Antibody (Brigham and Women's patent anti-ABCB5, Research Use) | NBR-0536 |
Nimacimab | CNR1 | Human CB1 / CNR1 Antibody (Nimacimab, Research Use) | NBR-0537 |
Carlumab | CCL2 | Human CCL2 / MCP1 Antibody (Carlumab, Research Use) | NBR-0538 |
NI-0701 | CCL5 | Human CCL5 / RANTES Antibody (NI-0701, Research Use) | NBR-0539 |
Pierre Fabre patent anti-CD151 | CD151 | Human CD151 Antibody (Pierre Fabre patent anti-CD151, Research Use) | NBR-0540 |
Centocor patent anti-CD147 | BSG | Human EMMPRIN / CD147 Antibody (Centocor patent anti-CD147, Research Use) | NBR-0541 |
Denintuzumab | CD19 | Human CD19 Antibody (Denintuzumab, Research Use) | NBR-0542 |
Duke U. patent anti-CD19 | CD19 | Human CD19 Antibody (Duke U. patent anti-CD19, Research Use) | NBR-0543 |
Centocor patent anti-IL-25 | IL25 | Human IL-25 Antibody (Centocor patent anti-IL-25, Research Use) | NBR-0544 |
CertolizumAb | TNFSF2 | Human TNFSF2 / TNFa Antibody (CertolizumAb, Research Use) | NBR-0545 |
Siplizumab | CD2 | Human CD2 Antibody (Siplizumab, Research Use) | NBR-0546 |
Chinese CDC patent anti-Interferon Alpha | IFNA1 | Human IFNa1 Antibody (Chinese CDC patent anti-Interferon Alpha, Research Use) | NBR-0547 |
CNTO 2125 | APP | Human Amyloid Beta Antibody (CNTO 2125, Research Use) | NBR-0548 |
CNTO 607 | IL13 | Human IL-13 Antibody (CNTO 607, Research Use) | NBR-0549 |
CNTO5429 | TLR3 | Human TLR3 / CD283 Antibody (CNTO5429, Research Use) | NBR-0550 |
Cobolimab | HAVCR2 | Human TIM-3 / HAVCR2 / CD366 Antibody (Cobolimab, Research Use) | NBR-0551 |
Cofetuzumab | PTK7 | Human PTK7 / CCK4 Antibody (Cofetuzumab, Research Use) | NBR-0552 |
Coltuximab | CD19 | Human CD19 Antibody (Coltuximab, Research Use) | NBR-0553 |
Concizumab | TFPI | Human TFPI Antibody (Concizumab, Research Use) | NBR-0554 |
Ripertamab | CD20 | Human CD20 Antibody (Ripertamab, Research Use) | NBR-0555 |
TRU-015 | CD20 | Human CD20 Antibody (TRU-015, Research Use) | NBR-0556 |
Ublituximab | CD20 | Human CD20 Antibody (Ublituximab, Research Use) | NBR-0557 |
Veltuzumab | CD20 | Human CD20 Antibody (Veltuzumab, Research Use) | NBR-0558 |
Zuberitamab | CD20 | Human CD20 Antibody (Zuberitamab, Research Use) | NBR-0559 |
FR104 | CD28 | Human CD28 Antibody (FR104, Research Use) | NBR-0560 |
Galiximab | CD80 | Human CD28L / CD80 Antibody (Galiximab, Research Use) | NBR-0561 |
Coprelotamab | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (Coprelotamab, Research Use) | NBR-0562 |
Cosibelimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Cosibelimab, Research Use) | NBR-0563 |
Crovalimab | C5 | Human Complement C5 Antibody (Crovalimab, Research Use) | NBR-0564 |
CSIRO anti-amyloid Beta scFv | APP | Human Amyloid Beta Antibody (CSIRO anti-amyloid Beta scFv, Research Use) | NBR-0565 |
Cudarolimab | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (Cudarolimab, Research Use) | NBR-0566 |
Dalotuzumab | IGF1R | Human IGF1R / CD221 Antibody (Dalotuzumab, Research Use) | NBR-0567 |
Dapirolizumab | CD40LG | Human TNFSF5 / CD40L / CD154 Antibody (Dapirolizumab, Research Use) | NBR-0568 |
Visilizumab | CD3E | Human CD3 Antibody (Visilizumab, Research Use) | NBR-0569 |
ITRI patent anti-CD34 | CD34 | Human CD34 Antibody (ITRI patent anti-CD34, Research Use) | NBR-0570 |
Felzartamab | CD38 | Human CD38 Antibody (Felzartamab, Research Use) | NBR-0571 |
Isatuximab | CD38 | Human CD38 Antibody (Isatuximab, Research Use) | NBR-0572 |
Mezagitamab | CD38 | Human CD38 Antibody (Mezagitamab, Research Use) | NBR-0573 |
Ibalizumab | CD4 | Human CD4 Antibody (Ibalizumab, Research Use) | NBR-0574 |
Tregalizumab | CD4 | Human CD4 Antibody (Tregalizumab, Research Use) | NBR-0575 |
TRX1 | CD4 | Human CD4 Antibody (TRX1, Research Use) | NBR-0576 |
Depemokimab | IL-5 | Human IL-5 Antibody (Depemokimab, Research Use) | NBR-0577 |
Derlotuximab | H1-0 | Human Histone H1 Antibody (Derlotuximab, Research Use) | NBR-0578 |
Divozilimab | CD20 | Human CD20 Antibody (Divozilimab, Research Use) | NBR-0579 |
Letaplimab | CD47 | Human CD47 Antibody (Letaplimab, Research Use) | NBR-0580 |
Ligufalimab | CD47 | Human CD47 Antibody (Ligufalimab, Research Use) | NBR-0581 |
LintuzumAb | CD33 | Human Siglec-3 / CD33 Antibody (LintuzumAb, Research Use) | NBR-0582 |
Urabrelimab | CD47 | Human CD47 Antibody (Urabrelimab, Research Use) | NBR-0583 |
Domantis patent anti-VEGF | VEGF | Human VEGF Antibody (Domantis patent anti-VEGF, Research Use) | NBR-0584 |
Dompe patent anti-FOLR1 | FOLR1 | Human FOLR1 Antibody (Dompe patent anti-FOLR1, Research Use) | NBR-0585 |
Gatralimab | CD52 | Human CD52 Antibody (Gatralimab, Research Use) | NBR-0586 |
Quark patent anti-CD59 | CD59 | Human CD59 Antibody (Quark patent anti-CD59, Research Use) | NBR-0587 |
Domvanalimab | TIGIT | Human TIGIT Antibody (Domvanalimab, Research Use) | NBR-0588 |
Donanemab | Amyloid Beta | Human Amyloid Beta Antibody (Donanemab, Research Use) | NBR-0589 |
GrisnilimAb | CD7 | Human CD7 Antibody (GrisnilimAb, Research Use) | NBR-0590 |
Dostarlimab | CD279 | Human PDCD1 / PD-1 / CD279 Antibody (Dostarlimab, Research Use) | NBR-0591 |
IladatuzumAb | CD79b | Human CD79b Antibody (IladatuzumAb, Research Use) | NBR-0592 |
Genentech patent anti-CD83 | CD83 | Human CD83 Antibody (Genentech patent anti-CD83, Research Use) | NBR-0593 |
Genentech patent anti-CD9 | CD9 | Human CD9 Antibody (Genentech patent anti-CD9, Research Use) | NBR-0594 |
Stem Centrx patent anti-Cadherin-1 | CD324 | Human CDH1 / E-cadherin / CD324 Antibody (Stem Centrx patent anti-Cadherin-1, Research Use) | NBR-0595 |
PF-03732010 | CDH3 | Human CDH3 / P-cadherin Antibody (PF-03732010, Research Use) | NBR-0596 |
Chaim Sheba Med. Cntr. patent anti-CEACAM1 | CD66a | Human CEACAM1 / CD66a Antibody (Chaim Sheba Med. Cntr. patent anti-CEACAM1, Research Use) | NBR-0597 |
CergutuzumAb | CD66e | Human CEACAM5 / CEA / CD66e Antibody (CergutuzumAb, Research Use) | NBR-0598 |
Ebdarokimab | IL-12b | Human IL-12b Antibody (Ebdarokimab, Research Use) | NBR-0599 |
Tusamitamab | CD66e | Human CEACAM5 / CEA / CD66e Antibody (Tusamitamab, Research Use) | NBR-0600 |
Ebronucimab | PCSK9 | Human PCSK9 Antibody (Ebronucimab, Research Use) | NBR-0601 |
Tinurilimab | CD66c | Human CEACAM6 / CD66c Antibody (Tinurilimab, Research Use) | NBR-0602 |
Academia Sinica patent anti-Clathrin Heavy Chain | CHC | Human Clathrin Heavy Chain / CHC Antibody (Academia Sinica patent anti-Clathrin Heavy Chain, Research Use) | NBR-0603 |
Elsilimomab | IL-6 | Human IL-6 / IFNb2 Antibody (Elsilimomab, Research Use) | NBR-0604 |
Emory U. anti-CD40 | CD40 | Human TNFRSF5 / CD40 Antibody (Emory U. anti-CD40, Research Use) | NBR-0605 |
BIIB059 | CLEC4C | Human CLEC4C Antibody (BIIB059, Research Use) | NBR-0606 |
Lendalizumab | Complement C5 | Human Complement C5 Antibody (Lendalizumab, Research Use) | NBR-0607 |
Ravulizumab | Complement C5 | Human Complement C5 Antibody (Ravulizumab, Research Use) | NBR-0608 |
Enoticumab | DLL4 | Human DLL4 Antibody (Enoticumab, Research Use) | NBR-0609 |
G2 patent anti-C5aR | Complement C5aR1 | Human Complement C5aR1 Antibody (G2 patent anti-C5aR, Research Use) | NBR-0610 |
Lampalizumab | Complement Factor D | Human Complement Factor D Antibody (Lampalizumab, Research Use) | NBR-0611 |
Epitomics patent anti-TNFα | TNFSF2 | Human TNFSF2 / TNFa Antibody (Epitomics patent anti-TNFα, Research Use) | NBR-0612 |
Emactuzumab | CSF1R | Human CSF1R / M-CSFR / CD115 Antibody (Emactuzumab, Research Use) | NBR-0613 |
LY3022855 | CSF1R | Human CSF1R / M-CSFR / CD115 Antibody (LY3022855, Research Use) | NBR-0614 |
Gimsilumab | CSF2 | Human CSF2 / GM-CSF Antibody (Gimsilumab, Research Use) | NBR-0615 |
Lenzilumab | CSF2 | Human CSF2 / GM-CSF Antibody (Lenzilumab, Research Use) | NBR-0616 |
Namilumab | CSF2 | Human CSF2 / GM-CSF Antibody (Namilumab, Research Use) | NBR-0617 |
Etrolizumab | ITGA4 & ITGB7 | Human Integrin a4b7 (ITGA4 & ITGB7) Antibody (Etrolizumab, Research Use) | NBR-0618 |
Evolocumab | PCSK9 | Human PCSK9 Antibody (Evolocumab, Research Use) | NBR-0619 |
Expression DD patent anti-SIP | Sphingosine-1-phosphate | Human Sphingosine-1-phosphate Antibody (Expression DD patent anti-SIP, Research Use) | NBR-0620 |
Finotonlimab | CD279 | Human PDCD1 / PD-1 / CD279 Antibody (Finotonlimab, Research Use) | NBR-0621 |
Flanvotumab | TRP1 | Human TRP1 / TYRP1 Antibody (Flanvotumab, Research Use) | NBR-0622 |
Nurulimab | CD152 | Human CTLA-4 / CD152 Antibody (Nurulimab, Research Use) | NBR-0623 |
Tremelimumab | CD152 | Human CTLA-4 / CD152 Antibody (Tremelimumab, Research Use) | NBR-0624 |
Zalifrelimab | CD152 | Human CTLA-4 / CD152 Antibody (Zalifrelimab, Research Use) | NBR-0625 |
CAT-2200 | CTLA-8 | Human CTLA-8 / IL-17a Antibody (CAT-2200, Research Use) | NBR-0626 |
Ixekizumab | CTLA-8 | Human CTLA-8 / IL-17a Antibody (Ixekizumab, Research Use) | NBR-0627 |
Netakimab | CTLA-8 | Human CTLA-8 / IL-17a Antibody (Netakimab, Research Use) | NBR-0628 |
Perakizumab | CTLA-8 | Human CTLA-8 / IL-17a Antibody (Perakizumab, Research Use) | NBR-0629 |
UCB patent anti-IL-17 | CTLA-8 | Human CTLA-8 / IL-17a Antibody (UCB patent anti-IL-17, Research Use) | NBR-0630 |
Vunakizumab | CTLA-8 | Human CTLA-8 / IL-17a Antibody (Vunakizumab, Research Use) | NBR-0631 |
Fontolizumab | IFNg | Human IFNg Antibody (Fontolizumab, Research Use) | NBR-0632 |
NI-0801 | CXCL10 | Human CXCL10 / IP-10 Antibody (NI-0801, Research Use) | NBR-0633 |
Genentech anti-CXCL12 | CXCL12 | Human CXCL12 / SDF1a Antibody (Genentech anti-CXCL12, Research Use) | NBR-0634 |
ABX-IL8 | CXCL8 | Human CXCL8 / IL-8 Antibody (ABX-IL8, Research Use) | NBR-0635 |
Genentech patent anti-IL-8 | CXCL8 | Human CXCL8 / IL-8 Antibody (Genentech patent anti-IL-8, Research Use) | NBR-0636 |
Foralumab | CD3e | Human CD3e Antibody (Foralumab, Research Use) | NBR-0637 |
Dana-Farber patent anti-CXCR4 | CXCR4 | Human CXCR4 / CD184 Antibody (Dana-Farber patent anti-CXCR4, Research Use) | NBR-0638 |
Forerunner patent anti-ICAM-3 | ICAM3 | Human ICAM3 / CD50 Antibody (Forerunner patent anti-ICAM-3, Research Use) | NBR-0639 |
Forerunner patent anti-Muc 17 | MUC17 | Human MUC17 Antibody (Forerunner patent anti-Muc 17, Research Use) | NBR-0640 |
Fox Chase patent anti-TEM7R | PLXDC2 | Human TEM7R / PLXDC2 Antibody (Fox Chase patent anti-TEM7R, Research Use) | NBR-0641 |
Fresolimumab | TGFB1 | Human TGFb1 Antibody (Fresolimumab, Research Use) | NBR-0642 |
Frovocimab | PCSK9 | Human PCSK9 Antibody (Frovocimab, Research Use) | NBR-0643 |
Smart Targeting patent anti-DLL4 | DLL4 | Human DLL4 Antibody (Smart Targeting patent anti-DLL4, Research Use) | NBR-0644 |
Gancotamab | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (Gancotamab, Research Use) | NBR-0645 |
Gatipotuzumab | MUC1 | Human MUC1 Antibody (Gatipotuzumab, Research Use) | NBR-0646 |
Parsatuzumab | EGFL7 | Human EGFL7 Antibody (Parsatuzumab, Research Use) | NBR-0647 |
Genentech patent anti-Factor B | CFB | Human Complement Factor B Antibody (Genentech patent anti-Factor B, Research Use) | NBR-0648 |
Genentech patent anti-Notch3 | NOTCH3 | Human NOTCH3 Antibody (Genentech patent anti-Notch3, Research Use) | NBR-0649 |
Adecatumumab | EPCAM | Human EpCAM / TROP1 / CD326 Antibody (Adecatumumab, Research Use) | NBR-0650 |
Georgetown U. patent anti-Amyloid Beta | APP | Human Amyloid Beta Antibody (Georgetown U. patent anti-Amyloid Beta, Research Use) | NBR-0651 |
Geptanolimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Geptanolimab, Research Use) | NBR-0652 |
Gevokizumab | IL-1b | Human IL-1b Antibody (Gevokizumab, Research Use) | NBR-0653 |
Giloralimab | CD40 | Human TNFRSF5 / CD40 Antibody (Giloralimab, Research Use) | NBR-0654 |
7A7 | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (7A7, Research Use) | NBR-0655 |
Chinese Mil.Med.Sci. patent anti-EGFR | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Chinese Mil.Med.Sci. patent anti-EGFR, Research Use) | NBR-0656 |
Demupitamab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Demupitamab, Research Use) | NBR-0657 |
Depatuxizumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Depatuxizumab, Research Use) | NBR-0658 |
Duke D2C7 | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Duke D2C7, Research Use) | NBR-0659 |
Imgatuzumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Imgatuzumab, Research Use) | NBR-0660 |
LaprituximAb | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (LaprituximAb, Research Use) | NBR-0661 |
Matuzumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Matuzumab, Research Use) | NBR-0662 |
Necitumumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Necitumumab, Research Use) | NBR-0663 |
Golimumab | TNFSF2 | Human TNFSF2 / TNFa Antibody (Golimumab, Research Use) | NBR-0664 |
Pimurutamab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Pimurutamab, Research Use) | NBR-0665 |
Shanghai Cancer Inst patent anti-EGFRvIII | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Shanghai Cancer Inst patent anti-EGFRvIII, Research Use) | NBR-0666 |
Zalutumumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Zalutumumab, Research Use) | NBR-0667 |
Ibritumomab | CD20 | Human CD20 Antibody (Ibritumomab, Research Use) | NBR-0668 |
Icatolimab | BTLA | Human BTLA / CD272 Antibody (Icatolimab, Research Use) | NBR-0669 |
Ifabotuzumab | EphA3 | Human EphA3 Antibody (Ifabotuzumab, Research Use) | NBR-0670 |
Hersintuzumab | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (Hersintuzumab, Research Use) | NBR-0671 |
Margetuximab | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (Margetuximab, Research Use) | NBR-0672 |
Timigutuzumab | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (Timigutuzumab, Research Use) | NBR-0673 |
Barecetamab | ERBB3 | Human ERBB3 / HER3 Antibody (Barecetamab, Research Use) | NBR-0674 |
Lumretuzumab | ERBB3 | Human ERBB3 / HER3 Antibody (Lumretuzumab, Research Use) | NBR-0675 |
Imclone 6.64 | KDR | Human VEGFR2 / KDR / CD309 Antibody (Imclone 6.64, Research Use) | NBR-0676 |
Immunomedics hA19 | CD19 | Human CD19 Antibody (Immunomedics hA19, Research Use) | NBR-0677 |
Abelacimab | F11 | Human F11 / Factor XI Antibody (Abelacimab, Research Use) | NBR-0678 |
Lumiliximab | FCER2 | Human FceR2 / CD23 Antibody (Lumiliximab, Research Use) | NBR-0679 |
DFRF4539A | FcRL5 | Human FcRL5 / IRTA2 Antibody (DFRF4539A, Research Use) | NBR-0680 |
Immunomedics patent anti-IGF-1R | IGF1R | Human IGF1R / CD221 Antibody (Immunomedics patent anti-IGF-1R, Research Use) | NBR-0681 |
Imperial College anti-DDR1 | DDR1 | Human DDR1 / CD167a Antibody (Imperial College anti-DDR1, Research Use) | NBR-0682 |
Lilly patent anti-FGFR-1 | FGFR1 | Human FGFR1 / CD331 Antibody (Lilly patent anti-FGFR-1, Research Use) | NBR-0683 |
INSERM patent anti-CO-029 | TSPAN8 | Human TSPAN8 Antibody (INSERM patent anti-CO-029, Research Use) | NBR-0684 |
Radretumab | FN1 | Human Fibronectin Antibody (Radretumab, Research Use) | NBR-0685 |
PelgifatamAb | FOLH1 | Human FOLH1 / PSMA Antibody (PelgifatamAb, Research Use) | NBR-0686 |
Iparomlimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Iparomlimab, Research Use) | NBR-0687 |
Vantictumab | FZD | Human FZD Antibody (Vantictumab, Research Use) | NBR-0688 |
Ivuxolimab | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (Ivuxolimab, Research Use) | NBR-0689 |
Jackson Foundation patent anti-ERG | ERG | Human ERG Antibody (Jackson Foundation patent anti-ERG, Research Use) | NBR-0690 |
Dinutuximab | N/A | Human GD2 Antibody (Dinutuximab, Research Use) | NBR-0691 |
EMD 273063 | N/A | Human GD2 Antibody (EMD 273063, Research Use) | NBR-0692 |
Korea Natl.Cancer Ctr. patent anti-GITR | TNFRSF18 | Human TNFRSF18 / GITR / CD357 Antibody (Korea Natl.Cancer Ctr. patent anti-GITR, Research Use) | NBR-0693 |
Korea RIBB patent anti-cMet | MET | Human HGFR / c-Met Antibody (Korea RIBB patent anti-cMet, Research Use) | NBR-0694 |
Kumamoto U. patent anti-Amyloid Beta | APP | Human Amyloid Beta Antibody (Kumamoto U. patent anti-Amyloid Beta, Research Use) | NBR-0695 |
Latozinemab | SORT1 | Human Sortilin / SORT1 Antibody (Latozinemab, Research Use) | NBR-0696 |
Lemzoparlimab | CD47 | Human CD47 Antibody (Lemzoparlimab, Research Use) | NBR-0697 |
Lilotomab | CD37 | Human TSPAN26 / CD37 Antibody (Lilotomab, Research Use) | NBR-0698 |
Lodapolimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Lodapolimab, Research Use) | NBR-0699 |
Lodelcizumab | PCSK9 | Human PCSK9 Antibody (Lodelcizumab, Research Use) | NBR-0700 |
Facet patent anti-GPR64 | ADGRG2 | Human GPR64 / ADGRG2 Antibody (Facet patent anti-GPR64, Research Use) | NBR-0701 |
LonigutamAb | IGF1R | Human IGF1R / CD221 Antibody (LonigutamAb, Research Use) | NBR-0702 |
LosatuxizumAb | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (LosatuxizumAb, Research Use) | NBR-0703 |
Ludwig-Maximilians U. anti_Hepsin | HAMP | Human Hepcidin / HAMP Antibody (Ludwig-Maximilians U. anti_Hepsin, Research Use) | NBR-0704 |
LY2787106 | HAMP | Human Hepcidin / HAMP Antibody (LY2787106, Research Use) | NBR-0705 |
Macrogenics patent anti-KID3 | KID3 | Human KID3 Antibody (Macrogenics patent anti-KID3, Research Use) | NBR-0706 |
TAK-701 | HGF | Human HGF / SF Antibody (TAK-701, Research Use) | NBR-0707 |
Metheresis patent anti-Met | MET | Human HGFR / c-Met Antibody (Metheresis patent anti-Met, Research Use) | NBR-0708 |
SAIT301 | MET | Human HGFR / c-Met Antibody (SAIT301, Research Use) | NBR-0709 |
Merck anti-Amyloid beta 19.3 | APP | Human Amyloid Beta Antibody (Merck anti-Amyloid beta 19.3, Research Use) | NBR-0710 |
Merck patent anti-Amyloid Beta | APP | Human Amyloid Beta Antibody (Merck patent anti-Amyloid Beta, Research Use) | NBR-0711 |
MirzotamAb | CD276 | Human B7-H3 / CD276 Antibody (MirzotamAb, Research Use) | NBR-0712 |
Modotuximab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Modotuximab, Research Use) | NBR-0713 |
Bersanlimab | ICAM1 | Human ICAM1 / CD54 Antibody (Bersanlimab, Research Use) | NBR-0714 |
MEDI-570 | ICOS | Human ICOS / CD278 Antibody (MEDI-570, Research Use) | NBR-0715 |
AMG 811 | IFNg | Human IFNg Antibody (AMG 811, Research Use) | NBR-0716 |
Emapalumab | IFNg | Human IFNg Antibody (Emapalumab, Research Use) | NBR-0717 |
Quilizumab | IGHE | Human IgE (M1 prime) Antibody (Quilizumab, Research Use) | NBR-0718 |
Ligelizumab | IGHE | Human IgE Antibody (Ligelizumab, Research Use) | NBR-0719 |
Mupadolimab | NT5E | Human NT5E / CD73 Antibody (Mupadolimab, Research Use) | NBR-0720 |
Talizumab | IGHE | Human IgE Antibody (Talizumab, Research Use) | NBR-0721 |
NaptumomAb | TPBG | Human TPBG Antibody (NaptumomAb, Research Use) | NBR-0722 |
Figitumumab | IGF1R | Human IGF1R / CD221 Antibody (Figitumumab, Research Use) | NBR-0723 |
Ganitumab | IGF1R | Human IGF1R / CD221 Antibody (Ganitumab, Research Use) | NBR-0724 |
NIH patent anti-Mesothelin | MSLN | Human Mesothelin Antibody (NIH patent anti-Mesothelin, Research Use) | NBR-0725 |
Nimotuzumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Nimotuzumab, Research Use) | NBR-0726 |
DX-2647 | IGF2 | Human IGF2 Antibody (DX-2647, Research Use) | NBR-0727 |
BT-063 | IL-10 | Human IL-10 Antibody (BT-063, Research Use) | NBR-0728 |
Briakinumab | IL-12a | Human IL-12 (IL-12a & IL-12b) Antibody (Briakinumab, Research Use) | NBR-0729 |
Nipocalimab | FcRn | Human FcRn (FCGRT & B2M) Antibody (Nipocalimab, Research Use) | NBR-0730 |
Abrezekimab | IL-13 | Human IL-13 Antibody (Abrezekimab, Research Use) | NBR-0731 |
Cendakimab | IL-13 | Human IL-13 Antibody (Cendakimab, Research Use) | NBR-0732 |
Dectrekumab | IL-13 | Human IL-13 Antibody (Dectrekumab, Research Use) | NBR-0733 |
GSK 679586 | IL-13 | Human IL-13 Antibody (GSK 679586, Research Use) | NBR-0734 |
H2L6 | IL-13 | Human IL-13 Antibody (H2L6, Research Use) | NBR-0735 |
IMA-026 | IL-13 | Human IL-13 Antibody (IMA-026, Research Use) | NBR-0736 |
Lebrikizumab | IL-13 | Human IL-13 Antibody (Lebrikizumab, Research Use) | NBR-0737 |
M1295 | IL-13 | Human IL-13 Antibody (M1295, Research Use) | NBR-0738 |
Nofazinlimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Nofazinlimab, Research Use) | NBR-0739 |
Novartis patent anti-CD45 | PTPRC | Human PTPRC / CD45 Antibody (Novartis patent anti-CD45, Research Use) | NBR-0740 |
DISC0280 | IL-15 | Human IL-15 Antibody (DISC0280, Research Use) | NBR-0741 |
ABT-325 | IL-18 | Human IL-18 Antibody (ABT-325, Research Use) | NBR-0742 |
Bermekimab | IL-1a | Human IL-1a Antibody (Bermekimab, Research Use) | NBR-0743 |
CDP484 | IL-1b | Human IL-1b Antibody (CDP484, Research Use) | NBR-0744 |
Novo Nordisk patent anti-Factor VIII | F8 | Human F8 / Factor VIII Antibody (Novo Nordisk patent anti-Factor VIII, Research Use) | NBR-0745 |
Melrilimab | IL-1RL1 | Human IL-1RL1 / ST2 / IL-33R Antibody (Melrilimab, Research Use) | NBR-0746 |
Cheng Kung U. patent anti-IL-20 | IL-20 | Human IL-20 Antibody (Cheng Kung U. patent anti-IL-20, Research Use) | NBR-0747 |
Avizakimab | IL-21 | Human IL-21 Antibody (Avizakimab, Research Use) | NBR-0748 |
Brazikumab | IL-23 | Human IL-23 Antibody (Brazikumab, Research Use) | NBR-0749 |
LY2525623 | IL-23 | Human IL-23 Antibody (LY2525623, Research Use) | NBR-0750 |
Mirikizumab | IL-23 | Human IL-23 Antibody (Mirikizumab, Research Use) | NBR-0751 |
Risankizumab | IL-23 | Human IL-23a Antibody (Risankizumab, Research Use) | NBR-0752 |
CamidanlumAb | IL-2Ra | Human IL-2Ra / CD25 Antibody (CamidanlumAb, Research Use) | NBR-0753 |
Ocaratuzumab | CD20 | Human CD20 Antibody (Ocaratuzumab, Research Use) | NBR-0754 |
Ociperlimab | TIGIT | Human TIGIT Antibody (Ociperlimab, Research Use) | NBR-0755 |
Ocrelizumab | CD20 | Human CD20 Antibody (Ocrelizumab, Research Use) | NBR-0756 |
Itepekimab | IL-33 | Human IL-33 Antibody (Itepekimab, Research Use) | NBR-0757 |
Ofatumumab | CD20 | Human CD20 Antibody (Ofatumumab, Research Use) | NBR-0758 |
MEDI2045 | IL-4Ra | Human IL-4Ra / CD124 Antibody (MEDI2045, Research Use) | NBR-0759 |
Abgenix anti-IL-5 | IL-5 | Human IL-5 Antibody (Abgenix anti-IL-5, Research Use) | NBR-0760 |
Okayama U. patent anti-oxLDL | OLR1 | Human oxLDL Antibody (Okayama U. patent anti-oxLDL, Research Use) | NBR-0761 |
Chugai SK2 | IL-6 | Human IL-6 / IFNb2 Antibody (Chugai SK2, Research Use) | NBR-0762 |
CSTRI patent anti-IL-6 | IL-6 | Human IL-6 / IFNb2 Antibody (CSTRI patent anti-IL-6, Research Use) | NBR-0763 |
Medarex patent anti-IL-6 | IL-6 | Human IL-6 / IFNb2 Antibody (Medarex patent anti-IL-6, Research Use) | NBR-0764 |
MEDI 5117 | IL-6 | Human IL-6 / IFNb2 Antibody (MEDI 5117, Research Use) | NBR-0765 |
Merck patent anti-IL-6 | IL-6 | Human IL-6 / IFNb2 Antibody (Merck patent anti-IL-6, Research Use) | NBR-0766 |
Olinvacimab | KDR | Human VEGFR2 / KDR / CD309 Antibody (Olinvacimab, Research Use) | NBR-0767 |
Siltuximab | IL-6 | Human IL-6 / IFNb2 Antibody (Siltuximab, Research Use) | NBR-0768 |
Sirukumab | IL-6 | Human IL-6 / IFNb2 Antibody (Sirukumab, Research Use) | NBR-0769 |
Ziltivekimab | IL-6 | Human IL-6 / IFNb2 Antibody (Ziltivekimab, Research Use) | NBR-0770 |
APX007 | IL-6Ra | Human IL-6Ra / CD126 Antibody (APX007, Research Use) | NBR-0771 |
Levilimab | IL-6Ra | Human IL-6Ra / CD126 Antibody (Levilimab, Research Use) | NBR-0772 |
Sapelizumab | IL-6Ra | Human IL-6Ra / CD126 Antibody (Sapelizumab, Research Use) | NBR-0773 |
Olokizumab | IL-6 | Human IL-6 / IFNb2 Antibody (Olokizumab, Research Use) | NBR-0774 |
Omalizumab | IGHE | Human IgE Antibody (Omalizumab, Research Use) | NBR-0775 |
Omburtamab | CD276 | Human B7-H3 / CD276 Antibody (Omburtamab, Research Use) | NBR-0776 |
PF-06342674 | IL-7Ra | Human IL-7Ra / CD127 Antibody (PF-06342674, Research Use) | NBR-0777 |
Ongericimab | PCSK9 | Human PCSK9 Antibody (Ongericimab, Research Use) | NBR-0778 |
Vatelizumab | ITGA2 & ITGB1 | Human Integrin a2b1 (ITGA2 & ITGB1) Antibody (Vatelizumab, Research Use) | NBR-0779 |
BMS patent anti-Integrin α5β1 | ITGA5 & ITGB1 | Human Integrin a5b1 (ITGA5 & ITGB1) Antibody (BMS patent anti-Integrin α5β1, Research Use) | NBR-0780 |
Efalizumab | ITGAL | Human Integrin aL / ITGAL / CD11a Antibody (Efalizumab, Research Use) | NBR-0781 |
Abituzumab | ITGAV | Human Integrin aV / ITGAV / CD51 Antibody (Abituzumab, Research Use) | NBR-0782 |
Intetumumab | ITGAV | Human Integrin aV / ITGAV / CD51 Antibody (Intetumumab, Research Use) | NBR-0783 |
Etaracizumab | ITGAV & ITGB3 | Human Integrin aVb3 (ITGAV & ITGB3) Antibody (Etaracizumab, Research Use) | NBR-0784 |
Opicinumab | LINGO1 | Human LINGO1 Antibody (Opicinumab, Research Use) | NBR-0785 |
Oportuzumab | EPCAM | Human EpCAM / TROP1 / CD326 Antibody (Oportuzumab, Research Use) | NBR-0786 |
Encelimab | LAG3 | Human LAG3 / CD223 Antibody (Encelimab, Research Use) | NBR-0787 |
Favezelimab | LAG3 | Human LAG3 / CD223 Antibody (Favezelimab, Research Use) | NBR-0788 |
Fianlimab | LAG3 | Human LAG3 / CD223 Antibody (Fianlimab, Research Use) | NBR-0789 |
Ieramilimab | LAG3 | Human LAG3 / CD223 Antibody (Ieramilimab, Research Use) | NBR-0790 |
Miptenalimab | LAG3 | Human LAG3 / CD223 Antibody (Miptenalimab, Research Use) | NBR-0791 |
Opucolimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Opucolimab, Research Use) | NBR-0792 |
LadiratuzumAb | SLC39A6 | Human LIV-1 / SLC39A6 Antibody (LadiratuzumAb, Research Use) | NBR-0793 |
Organon patent anti-CD27 | CD27 | Human TNFRSF7 / CD27 Antibody (Organon patent anti-CD27, Research Use) | NBR-0794 |
Orilanolimab | FCGRT | Human FcRn (FCGRT & B2M) Antibody (Orilanolimab, Research Use) | NBR-0795 |
Orticumab | OLR1 | Human oxLDL Antibody (Orticumab, Research Use) | NBR-0796 |
ORY012 | AXL | Human AXL / UFO Antibody (ORY012, Research Use) | NBR-0797 |
BMS-986148 | MSLN | Human Mesothelin Antibody (BMS-986148, Research Use) | NBR-0798 |
Osocimab | F11 | Human F11 / Factor XI Antibody (Osocimab, Research Use) | NBR-0799 |
Yeda patent anti-MMP-9 | MMP9 | Human MMP9 Antibody (Yeda patent anti-MMP-9, Research Use) | NBR-0800 |
Otelixizumab | CD3E | Human CD3 Antibody (Otelixizumab, Research Use) | NBR-0801 |
Otilimab | CSF2 | Human CSF2 / GM-CSF Antibody (Otilimab, Research Use) | NBR-0802 |
AR20.5 | MUC1 | Human MUC1 Antibody (AR20.5, Research Use) | NBR-0803 |
Otlertuzumab | CD37 | Human TSPAN26 / CD37 Antibody (Otlertuzumab, Research Use) | NBR-0804 |
Oxford Brookes U. patent anti-Activin Beta-B | INHBB | Human INHBB / Activin B Antibody (Oxford Brookes U. patent anti-Activin Beta-B, Research Use) | NBR-0805 |
Imaprelimab | MCAM | Human MUC18 / MCAM / CD146 Antibody (Imaprelimab, Research Use) | NBR-0806 |
AS2886401-00 | NGF | Human NGF / bNGF Antibody (AS2886401-00, Research Use) | NBR-0807 |
Fasinumab | NGF | Human NGF / bNGF Antibody (Fasinumab, Research Use) | NBR-0808 |
MEDI-578 | NGF | Human NGF / bNGF Antibody (MEDI-578, Research Use) | NBR-0809 |
PG110 | NGF | Human NGF / bNGF Antibody (PG110, Research Use) | NBR-0810 |
Uliledlimab | NT5E | Human NT5E / CD73 Antibody (Uliledlimab, Research Use) | NBR-0811 |
Pfizer patent anti-Notch1 | NOTCH1 | Human NOTCH1 Antibody (Pfizer patent anti-Notch1, Research Use) | NBR-0812 |
Vixarelimab | OSMR | Human OSMR Antibody (Vixarelimab, Research Use) | NBR-0813 |
ASK8007 | SPP1 | Human Osteopontin Antibody (ASK8007, Research Use) | NBR-0814 |
Plonmarlimab | CSF2 | Human CSF2 / GM-CSF Antibody (Plonmarlimab, Research Use) | NBR-0815 |
Ponezumab | APP | Human Amyloid Beta Antibody (Ponezumab, Research Use) | NBR-0816 |
Zelminemab | PAC1 | Human PAC1 Antibody (Zelminemab, Research Use) | NBR-0817 |
Ponsegromab | GDF15 | Human GDF15 / MIC-1 Antibody (Ponsegromab, Research Use) | NBR-0818 |
Amgen patent anti-PAR-2 | PAR2 | Human PAR2 Antibody (Amgen patent anti-PAR-2, Research Use) | NBR-0819 |
Pozelimab | C5 | Human Complement C5 Antibody (Pozelimab, Research Use) | NBR-0820 |
U.Penn. patent anti-PCLA | PLCA | Human PCLA Antibody (U.Penn. patent anti-PCLA, Research Use) | NBR-0821 |
Prolgolimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Prolgolimab, Research Use) | NBR-0822 |
Quark patent anti-ENDO 180 | MRC2 | Human MRC2 / CD280 Antibody (Quark patent anti-ENDO 180, Research Use) | NBR-0823 |
Quavonlimab | CTLA4 | Human CTLA-4 / CD152 Antibody (Quavonlimab, Research Use) | NBR-0824 |
Racotumomab | ST3GAL5 | Human GM3 Antibody (Racotumomab, Research Use) | NBR-0825 |
Merck patent anti-PCSK9 | PCSK9 | Human PCSK9 Antibody (Merck patent anti-PCSK9, Research Use) | NBR-0826 |
Ralpancizumab | PCSK9 | Human PCSK9 Antibody (Ralpancizumab, Research Use) | NBR-0827 |
Recaticimab | PCSK9 | Human PCSK9 Antibody (Recaticimab, Research Use) | NBR-0828 |
RG7652 | PCSK9 | Human PCSK9 Antibody (RG7652, Research Use) | NBR-0829 |
Schering patent anti-PCSK9 | PCSK9 | Human PCSK9 Antibody (Schering patent anti-PCSK9, Research Use) | NBR-0830 |
Regeneron patent anti-ASIC1 | ASIC1 | Human ASIC1 Antibody (Regeneron patent anti-ASIC1, Research Use) | NBR-0831 |
Balstilimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Balstilimab, Research Use) | NBR-0832 |
Budigalimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Budigalimab, Research Use) | NBR-0833 |
Cetrelimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Cetrelimab, Research Use) | NBR-0834 |
Regeneron patent anti-CD20 | CD20 | Human CD20 Antibody (Regeneron patent anti-CD20, Research Use) | NBR-0835 |
Ezabenlimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Ezabenlimab, Research Use) | NBR-0836 |
Regeneron patent anti-EGFR | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Regeneron patent anti-EGFR, Research Use) | NBR-0837 |
Regeneron patent anti-PAR-2 | PAR2 | Human PAR2 Antibody (Regeneron patent anti-PAR-2, Research Use) | NBR-0838 |
Penpulimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Penpulimab, Research Use) | NBR-0839 |
Pidilizumab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Pidilizumab, Research Use) | NBR-0840 |
Pimivalimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Pimivalimab, Research Use) | NBR-0841 |
Retifanlimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Retifanlimab, Research Use) | NBR-0842 |
Sasanlimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Sasanlimab, Research Use) | NBR-0843 |
Serplulimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Serplulimab, Research Use) | NBR-0844 |
Sintilimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Sintilimab, Research Use) | NBR-0845 |
Tislelizumab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Tislelizumab, Research Use) | NBR-0846 |
UCB patent anti-PD-1 | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (UCB patent anti-PD-1, Research Use) | NBR-0847 |
Zimberelimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Zimberelimab, Research Use) | NBR-0848 |
Revdofilimab | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (Revdofilimab, Research Use) | NBR-0849 |
RO5458640 | TNFSF12 | Human TNFSF12 / TWEAK Antibody (RO5458640, Research Use) | NBR-0850 |
IMC-2C5 | PDGFRB | Human PDGFRB / CD140b Antibody (IMC-2C5, Research Use) | NBR-0851 |
Robatumumab | IGF1R | Human IGF1R / CD221 Antibody (Robatumumab, Research Use) | NBR-0852 |
Bavituximab | N/A | Human Phosphatidylserine Antibody (Bavituximab, Research Use) | NBR-0853 |
Roche patent anti-ANG-2 | ANGPT2 | Human ANGPT2 Antibody (Roche patent anti-ANG-2, Research Use) | NBR-0854 |
Roche patent anti-CCN1 | CCN1 | Human CYR61 / CCN1 Antibody (Roche patent anti-CCN1, Research Use) | NBR-0855 |
BAY 1158061 | PRLR | Human PRLR / Prolactin Receptor Antibody (BAY 1158061, Research Use) | NBR-0856 |
Rockefeller U. patent anti-Amyloid Beta | APP | Human Amyloid Beta Antibody (Rockefeller U. patent anti-Amyloid Beta, Research Use) | NBR-0857 |
Roledumab | CD240d | Human RHD / CD240d Antibody (Roledumab, Research Use) | NBR-0858 |
Medella patent anti-RAMP-3 | RAMP3 | Human RAMP3 Antibody (Medella patent anti-RAMP-3, Research Use) | NBR-0859 |
LFB Anti-RhD | CD240d | Human RHD / CD240d Antibody (LFB Anti-RhD, Research Use) | NBR-0860 |
Atinumab | RTN4 | Human RTN4 / NOGO Antibody (Atinumab, Research Use) | NBR-0861 |
NG-101 | RTN4 | Human RTN4 / NOGO Antibody (NG-101, Research Use) | NBR-0862 |
LK-1 | S100A4 | Human S100A4 Antibody (LK-1, Research Use) | NBR-0863 |
SBI Biotech patent anti-BST2 | BST2 | Human BST2 / CD317 Antibody (SBI Biotech patent anti-BST2, Research Use) | NBR-0864 |
AB-25E9 | SIGLEC15 | Human Siglec-15 / CD33L3 Antibody (AB-25E9, Research Use) | NBR-0865 |
Medimmune patent anti-Siglec-15 | SIGLEC15 | Human Siglec-15 / CD33L3 Antibody (Medimmune patent anti-Siglec-15, Research Use) | NBR-0866 |
Epratuzumab | CD22 | Human Siglec-2 / CD22 Antibody (Epratuzumab, Research Use) | NBR-0867 |
NCI m971 | CD22 | Human Siglec-2 / CD22 Antibody (NCI m971, Research Use) | NBR-0868 |
NCI m972 | CD22 | Human Siglec-2 / CD22 Antibody (NCI m972, Research Use) | NBR-0869 |
Pinatuzumab | CD22 | Human Siglec-2 / CD22 Antibody (Pinatuzumab, Research Use) | NBR-0870 |
IMGN779 | CD22 | Human Siglec-3 / CD33 Antibody (IMGN779, Research Use) | NBR-0871 |
AzintuxizumAb | SLAMF7 | Human SLAMF7 / CS1 Antibody (AzintuxizumAb, Research Use) | NBR-0872 |
PDL241 | SLAMF7 | Human SLAMF7 / CS1 Antibody (PDL241, Research Use) | NBR-0873 |
VB1-050 | SLC2A8 | Human SLC2A8 Antibody (VB1-050, Research Use) | NBR-0874 |
LifastuzumAb | SLC34A2 | Human SLC34A2 Antibody (LifastuzumAb, Research Use) | NBR-0875 |
Upifitamab | SLC34A2 | Human SLC34A2 Antibody (Upifitamab, Research Use) | NBR-0876 |
Solanezumab | APP | Human Amyloid Beta Antibody (Solanezumab, Research Use) | NBR-0877 |
Sonepcizumab | SGPP1 | Human Sphingosine-1-phosphate Antibody (Sonepcizumab, Research Use) | NBR-0878 |
Tadocizumab | ITGA2 & ITGB3 | Human Integrin a2b3 (ITGA2 & ITGB3) Antibody (Tadocizumab, Research Use) | NBR-0879 |
Bepranemab | MAPT | Human Tau Antibody (Bepranemab, Research Use) | NBR-0880 |
Tafolecimab | PCSK9 | Human PCSK9 Antibody (Tafolecimab, Research Use) | NBR-0881 |
LY3022859 | TGFBR2 | Human TBFbR2 Antibody (LY3022859, Research Use) | NBR-0882 |
NKTT320 | PTCRA | Human TCR Antibody (NKTT320, Research Use) | NBR-0883 |
Telazorlimab | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (Telazorlimab, Research Use) | NBR-0884 |
Tenatumomab | TNC | Human Tenascin C Antibody (Tenatumomab, Research Use) | NBR-0885 |
Marstacimab | TFPI | Human TFPI Antibody (Marstacimab, Research Use) | NBR-0886 |
NIS793 | TGFB1 | Human TGFb1 Antibody (NIS793, Research Use) | NBR-0887 |
Zampilimab | TGM2 | Human TGM2 / Transglutaminase 2 Antibody (Zampilimab, Research Use) | NBR-0888 |
Etigilimab | TIGIT | Human TIGIT Antibody (Etigilimab, Research Use) | NBR-0889 |
Tesidolumab | C5 | Human Complement C5 Antibody (Tesidolumab, Research Use) | NBR-0890 |
Theraclone patent anti-GM-CSF | CSF2 | Human CSF2 / GM-CSF Antibody (Theraclone patent anti-GM-CSF, Research Use) | NBR-0891 |
Tilavonemab | MAPT | Human Tau Antibody (Tilavonemab, Research Use) | NBR-0892 |
Chugai patent anti-TF | TF | Human Tissue factor / CD142 Antibody (Chugai patent anti-TF, Research Use) | NBR-0893 |
Tilogotamab | TNFRSF10B | Human TNFRSF10B / TRAILR2 / CD262 Antibody (Tilogotamab, Research Use) | NBR-0894 |
TNX-832 | TF | Human Tissue factor / CD142 Antibody (TNX-832, Research Use) | NBR-0895 |
Benufutamab | TNFRSF10B | Human TNFRSF10B / TRAILR2 / CD262 Antibody (Benufutamab, Research Use) | NBR-0896 |
TOL101 | PTCRA | Human TCR Antibody (TOL101, Research Use) | NBR-0897 |
Lexatumumab | TNFRSF10B | Human TNFRSF10B / TRAILR2 / CD262 Antibody (Lexatumumab, Research Use) | NBR-0898 |
Tomuzotuximab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Tomuzotuximab, Research Use) | NBR-0899 |
Toray patent anti-Caprin-1 | CAPRIN1 | Human CAPRIN1 Antibody (Toray patent anti-Caprin-1, Research Use) | NBR-0900 |
Toripalimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Toripalimab, Research Use) | NBR-0901 |
BMS-986178 | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (BMS-986178, Research Use) | NBR-0902 |
Torudokimab | IL-33 | Human IL-33 Antibody (Torudokimab, Research Use) | NBR-0903 |
Tozorakimab | IL-33 | Human IL-33 Antibody (Tozorakimab, Research Use) | NBR-0904 |
U.Illinois scFv59 | APP | Human Amyloid Beta Antibody (U.Illinois scFv59, Research Use) | NBR-0905 |
Iscalimab | CD40 | Human TNFRSF5 / CD40 Antibody (Iscalimab, Research Use) | NBR-0906 |
Lucatumumab | CD40 | Human TNFRSF5 / CD40 Antibody (Lucatumumab, Research Use) | NBR-0907 |
Mitazalimab | CD40 | Human TNFRSF5 / CD40 Antibody (Mitazalimab, Research Use) | NBR-0908 |
Ravagalimab | CD40 | Human TNFRSF5 / CD40 Antibody (Ravagalimab, Research Use) | NBR-0909 |
U.Rochester patent anti-DC-STAMP | DCSTAMP | Human DCSTAMP Antibody (U.Rochester patent anti-DC-STAMP, Research Use) | NBR-0910 |
Pateclizumab | TNFSF1 | Human TNFSF1 / TNFb Antibody (Pateclizumab, Research Use) | NBR-0911 |
U.Washington patent anti-GAD65 | GAD2 | Human GAD65 Antibody (U.Washington patent anti-GAD65, Research Use) | NBR-0912 |
U.Washington patent anti-MICB | MICB | Human MICB Antibody (U.Washington patent anti-MICB, Research Use) | NBR-0913 |
Sibeprenlimab | TNFSF13 | Human TNFSF13 / APRIL / CD256 Antibody (Sibeprenlimab, Research Use) | NBR-0914 |
Tabalumab | TNFSF13B | Human TNFSF13B / BAFF / CD257 Antibody (Tabalumab, Research Use) | NBR-0915 |
SAR252067 | TNFSF14 | Human TNFSF14 / LIGHT / CD258 Antibody (SAR252067, Research Use) | NBR-0916 |
CDP571 | TNFSF2 | Human TNFSF2 / TNFa Antibody (CDP571, Research Use) | NBR-0917 |
U.Zurich patent anti-Amyloid Beta | APP | Human Amyloid Beta Antibody (U.Zurich patent anti-Amyloid Beta, Research Use) | NBR-0918 |
CMAB008 | TNFSF2 | Human TNFSF2 / TNFa Antibody (CMAB008, Research Use) | NBR-0919 |
ESBA 105 | TNFSF2 | Human TNFSF2 / TNFa Antibody (ESBA 105, Research Use) | NBR-0920 |
HMAK195 | TNFSF2 | Human TNFSF2 / TNFa Antibody (HMAK195, Research Use) | NBR-0921 |
Vedolizumab | ITGA4 & ITGB7 | Human Integrin a4b7 (ITGA4 & ITGB7) Antibody (Vedolizumab, Research Use) | NBR-0922 |
Ruplizumab | CD40LG | Human TNFSF5 / CD40L / CD154 Antibody (Ruplizumab, Research Use) | NBR-0923 |
Vibostolimab | TIGIT | Human TIGIT Antibody (Vibostolimab, Research Use) | NBR-0924 |
Vilobelimab | C5 | Human Complement C5 Antibody (Vilobelimab, Research Use) | NBR-0925 |
Wyeth patent anti-5T4 | TPBG | Human TPBG Antibody (Wyeth patent anti-5T4, Research Use) | NBR-0926 |
Rinat patent anti-TrkB | NTRK2 | Human TrkB / NTRK2 Antibody (Rinat patent anti-TrkB, Research Use) | NBR-0927 |
Schering patent anti-TSLP | TSLP | Human TSLP Antibody (Schering patent anti-TSLP, Research Use) | NBR-0928 |
AGS67E | CD37 | Human TSPAN26 / CD37 Antibody (AGS67E, Research Use) | NBR-0929 |
Volociximab | ITGA5 & ITGB1 | Human Integrin a5b1 (ITGA5 & ITGB1) Antibody (Volociximab, Research Use) | NBR-0930 |
Vonlerizumab | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (Vonlerizumab, Research Use) | NBR-0931 |
Hanwha patent anti-VCAM-1 | VCAM1 | Human VCAM1 / CD106 Antibody (Hanwha patent anti-VCAM-1, Research Use) | NBR-0932 |
Zagotenemab | MAPT | Human Tau Antibody (Zagotenemab, Research Use) | NBR-0933 |
Ranibizumab | VEGFA | Human VEGFA Antibody (Ranibizumab, Research Use) | NBR-0934 |
Varisacumab | VEGFA | Human VEGFA Antibody (Varisacumab, Research Use) | NBR-0935 |
VGX100 | VEGFC | Human VEGFC Antibody (VGX100, Research Use) | NBR-0936 |
AlacizumAb | KDR | Human VEGFR2 / KDR / CD309 Antibody (AlacizumAb, Research Use) | NBR-0937 |
AT001 | KDR | Human VEGFR2 / KDR / CD309 Antibody (AT001, Research Use) | NBR-0938 |
Vulinacimab | KDR | Human VEGFR2 / KDR / CD309 Antibody (Vulinacimab, Research Use) | NBR-0939 |
LY3022856 | FLT4 | Human VEGFR3 / FLT4 Antibody (LY3022856, Research Use) | NBR-0940 |
Bapineuzumab | APP | Human Amyloid Beta Antibody (Bapineuzumab, Research Use) | NBR-0941 |
Lecanemab | APP | Human Amyloid Beta Antibody (Lecanemab, Research Use) | NBR-0942 |
Antitope patent anti-CTLA4 | CD152 | Human CTLA-4 / CD152 Antibody (Antitope patent anti-CTLA4, Research Use) | NBR-0943 |
BioMab patent anti-Her2 | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (BioMab patent anti-Her2, Research Use) | NBR-0944 |
BioMab patent anti-VEGF | VEGFA | Human VEGF Antibody (BioMab patent anti-VEGF, Research Use) | NBR-0945 |
Centocor patent anti-GLP-1R | GLP1R | Human GLP1R Antibody (Centocor patent anti-GLP-1R, Research Use) | NBR-0946 |
Axatilimab | CSF1R | Human CSF1R / M-CSFR / CD115 Antibody (Axatilimab, Research Use) | NBR-0947 |
Immunomedics patent anti-CEACAM5 (Class III) | CD66a | Human CEACAM5 / CEA / CD66e Antibody (Immunomedics patent anti-CEACAM5 (Class III), Research Use) | NBR-0948 |
Naxitamab | Human GD2 Antibody (Naxitamab, Research Use) | NBR-0949 | |
Medarex patent anti-IFNAR-1 | IFNAR1 | Human IFNARa1 Antibody (Medarex patent anti-IFNAR-1, Research Use) | NBR-0950 |
Obexelimab | CD19 | Human CD19 Antibody (Obexelimab, Research Use) | NBR-0951 |
Genzyme patent anti-TGF-β | TGFB1 | Human TGFb1 Antibody (Genzyme patent anti-TGF-β, Research Use) | NBR-0952 |
Tezepelumab | TSLP | Human TSLP Antibody (Tezepelumab, Research Use) | NBR-0953 |
IgG1+Kappa Isotype Control | ABM | Human Abm Antibody (IgG1+Kappa Isotype Control, Research Use) | NBR-0954 |
IgG4+Kappa Isotype Control | ABM | Human Abm Antibody (IgG4+Kappa Isotype Control, Research Use) | NBR-0955 |
Pritoxaximab | Shiga toxin (E.coli) | Human Shiga toxin (E.coli) Antibody (Pritoxaximab, Research Use) | NBR-0956 |
Setoxaximab | Shiga toxin (E.coli) | Human Shiga toxin (E.coli) Antibody (Setoxaximab, Research Use) | NBR-0957 |
OST 577 | HBsAg | Human HBsAg Antibody (OST 577, Research Use) | NBR-0958 |
Foravirumab | Rabies virus GP | Human Rabies virus GP Antibody (Foravirumab, Research Use) | NBR-0959 |
Rafivirumab | Rabies virus GP | Human Rabies virus GP Antibody (Rafivirumab, Research Use) | NBR-0960 |
Motavizumab | RSV-F | Human RSV-F Antibody (Motavizumab, Research Use) | NBR-0961 |
Palivizumab | RSV-F | Human RSV-F Antibody (Palivizumab, Research Use) | NBR-0962 |
Metelimumab | TGFB1 | Human TGFB1 Antibody (Metelimumab, Research Use) | NBR-0963 |
Bimekizumab | CTLA-8 | Human IL17A, IL-17F, IL17AF Antibody (Bimekizumab, Research Use) | NBR-0964 |
Panitumumab | VEGF | Human EGFR Antibody (Panitumumab, Research Use) | NBR-0965 |
Datopotamab | TACSTD2 | Human TROP2 Antibody (Datopotamab, Research Use) | NBR-0966 |
Praluzatamab-MMAE | ALCAM / CD166 | Anti-ALCAM / CD166 Reference Antibody (Praluzatamab-MMAE) | NBR-1000 |
Murlentamab-MMAE | AMHR2 | Anti-AMHR2 Reference Antibody (Murlentamab-MMAE) | NBR-1001 |
Enapotamab vedotin | AXL / UFO | Anti-AXL / UFO Reference Antibody (Enapotamab vedotin) | NBR-1002 |
Tilvestamab-MMAE | AXL / UFO | Anti-AXL / UFO Reference Antibody (Tilvestamab-MMAE) | NBR-1003 |
oregovomab-MMAE | CA125 / MUC16 | Anti-MUC16 Reference Antibody (oregovomab-MMAE) | NBR-1004 |
Sofituzumab vedotin | CA125 / MUC16 | Anti-MUC16 Reference Antibody (Sofituzumab vedotin) | NBR-1005 |
girentuximab-MMAE | CA9 / Carbonic anhydrase 9 | Anti-CA9 / CAIX Reference Antibody (girentuximab-MMAE) | NBR-1006 |
denintuzumab-MMAF | CD19 | Anti-CD19 Reference Antibody (denintuzumab-MMAF) | NBR-1007 |
Polatuzumab vedotin-piiq | CD79b | Anti-CD79b Reference Antibody (Polatuzumab vedotin-piiq) | NBR-1008 |
iladatuzumab vedotin | CD79b | Anti-CD79b Reference Antibody (iladatuzumab vedotin) | NBR-1009 |
labetuzumab govitecan | CEACAM5 / CEA / CD66e | Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab govitecan) | NBR-1010 |
Tusamitamab-MMAE | CEACAM5 / CEA / CD66e | Anti-CEACAM5 / CEA / CD66e Reference Antibody (Tusamitamab-MMAE) | NBR-1011 |
zolbetuximab MMAE | CLDN18.2 | Anti-CLDN18.2 Reference Antibody (zolbetuximab MMAE) | NBR-1012 |
ulocuplumab-MMAE | CXCR4 / CD184 | Anti-CXCR4/CD184 Reference Antibody (ulocuplumab-MMAE) | NBR-1013 |
rovalpituzumab-MMAE | DLL3 | Anti-DLL3 Reference Antibody (rovalpituzumab-MMAE) | NBR-1014 |
carotuximab-MMAE | Endoglin / CD105 | Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE) | NBR-1015 |
depatuxizumab-MMAF | ERBB1 / EGFR / HER1 | Anti-ERBB1 / EGFR / HER1 Reference Antibody (depatuxizumab-MMAF) | NBR-1016 |
Cetuximab-MMAE | ERBB1 / EGFR / HER1 | Anti-ERBB1 / EGFR / HER1 Reference Antibody (Cetuximab-MMAE) | NBR-1017 |
Disitamab vedotin | ERBB2 / HER2 / CD340 | Anti-ERBB2 / HER2 / CD340 Reference Antibody (Disitamab vedotin) | NBR-1018 |
Trastuzumab-MMAE | ERBB2 / HER2 / CD340 | Anti-ERBB2 / HER2 / CD340 Reference Antibody (Trastuzumab-MMAE) | NBR-1019 |
patritumab-MMAE | ERBB3 / HER3 | Anti-ERBB3/ HER3 Reference Antibody (patritumab-MMAE) | NBR-1020 |
Patritumab deruxtecan | ERBB3 / HER3 | Anti-ERBB3/ HER3 Reference Antibody (Patritumab deruxtecan) | NBR-1021 |
rosopatamab-MMAE | FOLH1 / PSMA | Anti-FOLH1 / PSMA Reference Antibody (rosopatamab-MMAE) | NBR-1022 |
farletuzumab-MMAE | FOLR1 / FRA | Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) | NBR-1023 |
mirvetuximab-MMAE | FOLR1 / FRA | Anti-FOLR1 / FRA Reference Antibody (mirvetuximab-MMAE) | NBR-1024 |
ecromeximab-MMAE | GD3 | Anti-GD3 Reference Antibody (ecromeximab-MMAE) | NBR-1025 |
Codrituzumab-MMAE | GPC3 / Glypican-3 | Anti-GPC3 / Glypican-3 Reference Antibody (Codrituzumab-MMAE) | NBR-1026 |
Glembatumumab vedotin | GPNMB | Anti-GPNMB Reference Antibody (Glembatumumab vedotin) | NBR-1027 |
Indusatumab vedotin | GUCY2C | Anti-GUCY2C Reference Antibody (Indusatumab vedotin) | NBR-1028 |
Telisotuzumab vedotin | HGFR / c-Met | Anti-HGFR / c-Met Reference Antibody (Telisotuzumab vedotin) | NBR-1029 |
talacotuzumab-MMAE | IL-3Ra / CD123 | Anti-IL-3Ra / CD123 Reference Antibody (talacotuzumab-MMAE) | NBR-1030 |
ADCT-901-MMAE | KAAG1 | Anti-KAAG1 Reference Antibody (ADCT-901-MMAE) | NBR-1031 |
Ladiratuzumab vedotin | LIV-1 / SLC39A6 | Anti-LIV-1 / SLC39A6 Reference Antibody (Ladiratuzumab vedotin) | NBR-1032 |
anetumab-MMAE | Mesothelin | Anti-Mesothelin Reference Antibody (anetumab-MMAE) | NBR-1033 |
ensituximab-MMAE | MU5AC | Anti-MU5AC Reference Antibody (ensituximab-MMAE) | NBR-1034 |
clivatuzumab-MMAE | MUC1 | Anti-MUC1 Reference Antibody (clivatuzumab-MMAE) | NBR-1035 |
Lifastuzumab vedotin | NaPi2b / SLC34A2 | Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) | NBR-1036 |
lorvotuzumab-MMAE | NCAM1 / CD56 | Anti-NCAM1 / CD56 Reference Antibody (lorvotuzumab-MMAE) | NBR-1037 |
enfortumab vedotin-ejfv | Nectin-4 | Anti-Nectin-4 Reference Antibody (enfortumab vedotin-ejfv) | NBR-1038 |
Zilovertamab vedotin | ROR1 | Anti-ROR1 Reference Antibody (Zilovertamab vedotin) | NBR-1039 |
ozuriftamab vedotin | ROR2 | Anti-ROR2 Reference Antibody (ozuriftamab vedotin) | NBR-1040 |
Pinatuzumab vedotin | Siglec-2 / CD22 | Anti-Siglec-2 / CD22 Reference Antibody (Pinatuzumab vedotin) | NBR-1041 |
inotuzumab-MMAE | Siglec-2 / CD22 | Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-MMAE) | NBR-1042 |
Sirtratumab vedotin | SLITRK6 | Anti-SLITRK6 Reference Antibody (Sirtratumab vedotin) | NBR-1043 |
tisotumab vedotin | TF / Factor III / Tissue Factor / CD142 | Anti-TF / Factor III / Tissue Factor / CD142 Reference Antibody (tisotumab vedotin) | NBR-1044 |
brentuximab vedotin | TNFRSF8 / CD30 | Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin) | NBR-1045 |
Vorsetuzumab mafodotin | TNFSF7 / CD27L / CD70 | Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) | NBR-1046 |
datopotamab deruxtecan | TROP2 | Anti-TROP2 Reference Antibody (datopotamab deruxtecan) | NBR-1047 |
Sacituzumab-MMAE | TROP2 | Anti-TROP2 Reference Antibody (Sacituzumab-MMAE) | NBR-1048 |
关键词:Alpha-fetoprotein抗体,CD19抗体,CD28抗体,CD40抗体,CD40L抗体,CD70抗体,B7-2抗体,CDK4抗体,CEACAM-5抗体,CTLA-4抗体,IL-8抗体,VEGFR2抗体,KRAS抗体,LAG-3抗体,TNFRSF5抗体,TNFSF5抗体,CD27抗体,CD86抗体,CD66e抗体,CXCL8抗体,KDR抗体,Anti-Alpha-fetoprotein,Anti-CD19,Anti-CD28,Anti-CD40,Anti-CD40L,Anti-CD70,Anti-B7-2,Anti-CDK4,Anti-CEACAM-5,Anti-CTLA-4,Anti-IL-8,Anti-VEGFR2,Anti-KRAS,Anti-LAG-3,Anti-TNFRSF5,Anti-TNFSF5,Anti-CD27,Anti-CD86,Anti-CD66e,Anti-CXCL8,Anti-KDR,抗Alpha-fetoprotein单抗,抗CD19单抗,抗CD28单抗,抗CD40单抗,抗CD40L单抗,抗CD70单抗,抗B7-2单抗,抗CDK4单抗,抗CEACAM-5单抗,抗CTLA-4单抗,抗IL-8单抗,抗VEGFR2单抗,抗KRAS单抗,抗LAG-3单抗,抗TNFRSF5单抗,抗TNFSF5单抗,抗CD27单抗,抗CD86单抗,抗CD66e单抗,抗CXCL8单抗,抗KDR单抗